Anti-tfpi antibody having binding specificity and use thereof
By developing antibodies that specifically bind to human TFPI, the issues of adherence and safety in factor replacement therapy have been resolved, resulting in more efficient and safer coagulation capabilities, suitable for the treatment of hemophilia and platelet disorders.
Patent Information
- Application Number
- PCT/CN2023/136763
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-05
- Filing Date
- 2023-12-06
- Publication Date
- 2024-12-12
AI Technical Summary
Existing factor replacement therapies for the prevention and treatment of hemophilia and platelet disorders suffer from poor adherence, high costs, and reduced efficacy due to frequent factor infusions. Furthermore, existing antibodies have insufficient circulating half-life, stability, and safety in vivo.
An antibody that specifically binds to human TFPI has been developed. By binding to specific amino acid sites of TFPI, it blocks FXa activity, activates the coagulation pathway, and provides a treatment option with a longer half-life and higher safety.
It improves coagulation ability, reduces the risk of thrombosis, enhances treatment adherence, reduces dosing frequency, and improves safety, making it suitable for the treatment of hemophilia and platelet disorders.
Smart Images

Figure PCTCN2023136763-FTAPPB-I100001 
Figure PCTCN2023136763-FTAPPB-I100002 
Figure PCTCN2023136763-FTAPPB-I100003
Abstract
Description
Specific binding anti-TFPI antibodies and uses thereof Technical Field
[0001] The present invention belongs to the field of therapeutic monoclonal antibodies. More specifically, the present invention relates to an antibody or an antigen-binding fragment thereof against tissue factor pathway inhibitor (TFPI); and also relates to the use of the antibody in the preparation of a drug for preventing or treating genetic or acquired coagulation diseases or events. Background Art
[0002] Hemophilia A and B are inherited bleeding disorders characterized by impaired active thromboplastin production, prolonged clotting time, and a lifelong tendency to bleed after minor trauma. Severely ill patients can experience spontaneous bleeding even without significant trauma. Hemophilia A, characterized by the absence or deficiency of coagulation factor VIII (FVIII), accounts for over 80% of all hemophilia cases, with a prevalence of 1 in 5,000 males. Hemophilia B, characterized by the absence or deficiency of coagulation factor IX (FIX), affects 1 in 30,000 newborns (Chowdary, P. Int J Hematol, 2020, 111:42–50). Recurrent, spontaneous, and trauma-related bleeding are hallmarks of severe hemophilia, typically in joints and muscles. With minimal treatment, severe patients can experience up to 30–40 bleeds per year, leading to irreversible joint damage and secondary disability. Currently, the most commonly used treatment is factor replacement therapy, which supplements the FVIII or FIX that hemophilia patients lack. Based on current treatment methods, preventive treatment requires frequent infusions of FVIII or FIX, usually 2 to 4 times a week, to reduce spontaneous bleeding. However, this treatment method can effectively prevent most spontaneous bleeding, but it cannot prevent traumatic bleeding. In addition, the effectiveness of the treatment is affected by the frequency of infusion, dosage, and the number of missed or delayed doses. The dosage and infusion frequency are affected by the elimination half-life of the factor, the cost-effectiveness of the regimen, and patient acceptability. In order to overcome the limitations of factor replacement therapy, improve patient compliance, and reduce the burden on patients, new treatment methods need to be explored.
[0003] Platelets are a major component of the blood system. When blood vessels are damaged, platelets play a role in hemostasis and blood clotting. A decrease in platelet count or impaired function can lead to impaired hemostasis and thrombosis, and can also cause related platelet diseases. Giant Platelet Syndrome, also known as Bernard-Soulier Syndrome, is a rare inherited bleeding disorder with an incidence of less than 1 in 1,000,000 individuals. It is primarily caused by defects in the synthesis and expression of the glycoprotein complex GPIb-IX-V on the platelet membrane, or genetic defects in any of its subunits, GPIb, GPIX, and GPV. GPIb-IX-V defects prevent platelets from properly adhering to the vascular endothelium, resulting in skin, mucosal, or internal bleeding of varying severity. Patients present with giant platelets and mild to moderate thrombocytopenia in their peripheral blood. First described by Glanzmann in 1918, thrombasthenia (GT) is also known as Glanzmann thrombasthenia (GT). It is an inherited bleeding disorder characterized by a low or absent response of blood cells to various physiological aggregating agents, caused by qualitative or quantitative abnormalities in platelet membrane glycoprotein IIb (GPIIb) and / or GPIIIa (GPIIIa). In 1990, the International Society on Thrombosis and Hemostasis Standardization Committee defined GT as a congenital hereditary failure of platelets to aggregate or a reduced response to various aggregating agents (such as adenosine diphosphate, thrombin, and collagen) due to defects in the GPIIb or GPIIIa genes.
[0004] Tissue factor pathway inhibitor (TFPI) is a naturally occurring anticoagulant protein in the body that controls the initiation of coagulation. It specifically inhibits the tissue factor-initiated coagulation pathway by binding to the TF / FVIIa complex, preventing factor X activation and thereby inhibiting coagulation. When TFPI activity is neutralized by anti-TFPI antibodies, coagulation is restored or amplified. TFPI is a 276-amino acid glycoprotein containing three Kunitz domains: K1, K2, and K3. It also includes two linker regions, an N-terminus rich in acidic amino acids, and a C-terminus rich in basic amino acids. Domains K1 and K2 are key to TFPI's anticoagulant activity. K3 is not essential for this action, but its presence enhances TFPI's ability to inhibit coagulation. Recent studies have demonstrated that K3 and the C-terminus can bind to heparin, membrane glycoproteins, and polysaccharides. Furthermore, this region is implicated in TFPI's anti-inflammatory effects. The inhibitory effect of TFPI in the coagulation pathway is achieved in two steps: first, TFPI binds to activated FⅩ through K2 and competitively inhibits its activity. This process is a Ca 2+An independent reversible process; secondly, TFPI in the FⅩa / TFPI complex binds to the FⅦa active site in the FⅦa / TF complex through K1, thereby inhibiting the FⅦa / TF complex. TFPI antibodies act on the K-2 region of TFPI, competitively blocking the site where FXa binds to TFPI, increasing FXa levels and also blocking the interaction of TFPI in FXa and Ca. 2+ The inhibitory effect on TF-FVIIa leads to increased levels of FXa and the generation of thrombin, improving coagulation ability through a dual mechanism.
[0005] Anti-TFPI antibodies can be used in patients with hemophilia, with or without FVIII and FIX inhibitors, giant platelet syndrome, and thrombasthenia. The antibodies themselves have a longer half-life, which can reduce the frequency of dosing. There is still a need in this field to explore therapeutic antibodies with improved performance in terms of in vivo circulation half-life, in vivo stability, drug safety, and manufacturability.
[0006] Summary of the Invention
[0007] The present invention provides an antibody that specifically binds to human TFPI and has good administration safety, a specific binding epitope of the antibody, a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell comprising the vector, a method for producing the antibody, and a pharmaceutical composition for preventing or treating coagulation disorders in patients with inherited or acquired coagulation factor deficiencies, the pharmaceutical composition comprising the antibody as an active ingredient and capable of inhibiting TFPI, thereby activating the coagulation pathway. The anti-human TFPI antibodies disclosed herein can be used to treat or prevent hemophilia.
[0008] In one aspect, the present invention provides an antibody or antigen-binding fragment thereof that specifically binds to TFPI, wherein the antibody or antigen-binding fragment thereof specifically binds to an epitope within residues K93-N152 of the amino acid sequence set forth in SEQ ID NO: 1, wherein the antibody or antigen-binding fragment thereof does not bind to the R107 site within 5 angstroms. Preferably, the antibody or antigen-binding fragment thereof interacts with and / or blocks at least one of the following amino acid sites within the epitope at a distance of 5 angstroms or less: Y109, I110, T111, R124, K126, and E138. Preferably, the closest distance between the CA atoms of the amino acid residues of the antibody or antigen-binding fragment thereof and the CA atoms of the TFPI R107 residue is greater than 9.0 angstroms.
[0009] Preferably, when the antibody or antigen-binding fragment thereof binds to TFPI, in addition to interacting and / or blocking at least one of amino acids Y109, I110, T111, R124, K126 or E138 at 5 angstroms or less, and not binding to the R107 site, it also interacts and / or blocks at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more of the following amino acids at 5 angstroms or less: T139, T119, E101, Y113, F114, N116, Q118, Q121, C122, E123, F125 and L140.
[0010] In certain aspects, when the antibody or antigen-binding fragment thereof binds to TFPI, in addition to interacting and / or blocking one of amino acids Y109, I110, T111, R124, K126 or E138 at 5 angstroms or less, and not binding to the R107 site, it also interacts and / or blocks one of the following amino acids at 5 angstroms or less: T139, T119, E101, Y113, F114, N116, Q118, Q121, C122, E123, F125 and L140 at 5 angstroms or less. In certain aspects, when the antibody or antigen-binding fragment thereof binds to TFPI, in addition to interacting and / or blocking two of amino acids Y109, I110, T111, R124, K126 or E138 at 5 angstroms or less, and not binding to the R107 site, it also interacts and / or blocks one of the following amino acids at 5 angstroms or less: T139, T119, E101, Y113, F114, N116, Q118, Q121, C122, E123, F125 and L140 at 5 angstroms or less. In certain aspects, when the antibody or antigen-binding fragment thereof binds to TFPI, in addition to interacting and / or blocking two of amino acids Y109, I110, T111, R124, K126 or E138 at 5 angstroms or less, and not binding to the R107 site, it also interacts and / or blocks two of the following amino acids at 5 angstroms or less: T139, T119, E101, Y113, F114, N116, Q118, Q121, C122, E123, F125 and L140 at 5 angstroms or less. In certain aspects, when the antibody or antigen-binding fragment thereof binds to TFPI, in addition to interacting and / or blocking three of amino acids Y109, I110, T111, R124, K126 or E138 at 5 angstroms or less, and not binding to the R107 site, it also interacts and / or blocks one of the following amino acids at 5 angstroms or less: T139, T119, E101, Y113, F114, N116, Q118, Q121, C122, E123, F125 and L140 at 5 angstroms or less.
[0011] Preferably, the antibody or antigen-binding fragment thereof specifically binds to at least one or more basic amino acids in the TFPI protein, wherein the basic amino acids are selected from R112, K93, K120, R124, K126 and K144, and preferably the basic amino acids are R124 and K126.
[0012] TFPI K2 R107 is a central amino acid in the FXa inhibitory active center. In certain embodiments, the shortest distance between the amino acid residue CA atom of the antibody or antigen-binding fragment thereof described herein and the amino acid residue R107 residue CA atom of TFPI K2 is 10.50 angstroms, which is between the antibody light chain Y95 and TFPI K2 R107 residues.
[0013] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region defined according to the Kabat numbering system comprises at least one, two or three complementarity determining regions (CDRs) selected from the following groups:
[0014] (1) HCDR1, which has an amino acid sequence of SYWMH;
[0015] (2) HCDR2 having an amino acid sequence of EIKPD X1GRI X2YNEKFKT, wherein X1 is selected from Q, H or K, and X2 is selected from N, D or H; and
[0016] (3) HCDR3 having an amino acid sequence of SS X3X4D X5A X6DY, wherein X3 is selected from V or H, X4 is selected from V, I, F, Y or L, X5 is selected from V, D, T or E, and X6 is selected from M, L, I, E, V or D;
[0017] and / or, the light chain variable region it comprises comprises at least one, two or three complementarity determining regions (CDRs) selected from the group consisting of:
[0018] (4) LCDR1, which has an amino acid sequence of SASSSVSSSYLY;
[0019] (5) LCDR2, which has the amino acid sequence of GTSILAS; and
[0020] (6) LCDR3 having an amino acid sequence such as HQWX7X8YPFT, wherein X7 is selected from S or T, and X8 is selected from H, Y or F.
[0021] Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region defined according to the IMGT numbering system comprises at least one, two or three complementarity determining regions (CDRs) selected from the following group:
[0022] (1) HCDR1, which has the amino acid sequence of GYTFTSYW;
[0023] (2) HCDR2 having the amino acid sequence of IKPD X1GRI, wherein X1 is selected from Q, H or K; and
[0024] (3) HCDR3 having an amino acid sequence of ARSS X3X4D X5A X6DY, wherein X3 is selected from V or H, X4 is selected from V, I, F, Y or L, X5 is selected from V, D, T or E, and X6 is selected from M, L, I, E, V or D;
[0025] and / or, the light chain variable region it comprises comprises at least one, two or three complementarity determining regions (CDRs) selected from the group consisting of:
[0026] (4) LCDR1, which has the amino acid sequence of SSVSSSY;
[0027] (5) LCDR2 having the amino acid sequence of GTS; and
[0028] (6) LCDR3 having an amino acid sequence such as HQWX7X8YPFT, wherein X7 is selected from S or T, and X8 is selected from H, Y or F.
[0029] In certain preferred embodiments, the HCDR1, HCDR2, and HCDR3 contained in the heavy chain variable region, and / or the LCDR1, LCDR2, and LCDR3 contained in the light chain variable region are defined by the Kabat or IMGT numbering system. Table 2 exemplifies the CDR amino acid sequences of preferred antibodies defined by the Kabat or IMGT numbering system.
[0030] In certain preferred embodiments, the antibody or antigen-binding fragment thereof comprises three VH variable region CDRs and three VL variable region CDRs defined according to the Kabat numbering system, which are selected from the following group:
[0031] (1) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 48, 49, 50 or 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0032] (2) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 56, 49, 50 or 51, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0033] (3) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 58, 49, 50 or 51, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0034] (4) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 60, 48, 49, 50 or 51, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0035] (5) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequence shown in SEQ ID NO: 46, 61, 48, 49, 50 or 51, respectively, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences
[0036] (6) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 63, 48, 49, 50 or 51, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0037] (7) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 65, 48, 49, 50 or 51, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0038] (8) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 48, 49, 50 or 66, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0039] (9) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 48, 49, 50 or 67, respectively, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0040] (10) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 48, 49, 50 or 68, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0041] (11) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 63, 58, 49, 50 or 51, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0042] (12) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 69, 49, 50 or 51, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0043] (13) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 71, 49, 50 or 51, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0044] (14) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 73, 49, 50 or 51, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0045] (15) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 75, 49, 50 or 51, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0046] (16) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 77, 49, 50 or 51, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0047] (17) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 79, 49, 50 or 51, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0048] (18) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 81, 49, 50 or 51, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0049] (19) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 83, 49, 50 or 51, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0050] (20) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 85, 49, 50 or 51, respectively, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0051] (21) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 87, 49, 50 or 51, respectively, or sequences having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0052] (22) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 89, 49, 50 or 51, respectively, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences.
[0053] In certain preferred embodiments, the substitutions described in any of the above are conservative substitutions.
[0054] In certain preferred embodiments, the antibody or antigen-binding fragment thereof comprises three VH variable region CDRs and three VL variable region CDRs defined according to the IMGT numbering system, which are selected from the group consisting of:
[0055] (1) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 54, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0056] (2) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 57, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0057] (3) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 59, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0058] (4) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 62, 54, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0059] (5) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 65, 54, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0060] (6) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 54, 55, Gly-Thr-Ser or SEQ ID NO: 66, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0061] (7) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 54, 55, Gly-Thr-Ser or SEQ ID NO: 67, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0062] (8) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 54, 55, Gly-Thr-Ser or SEQ ID NO: 68, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0063] (9) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 64, 59, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0064] (10) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 70, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0065] (11) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 72, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0066] (12) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 74, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0067] (13) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 76, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0068] (14) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 78, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0069] (15) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 80, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0070] (16) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 82, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0071] (17) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 84, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0072] (18) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 86, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0073] (19) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 88, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences;
[0074] (20) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 90, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared to any of the above sequences.
[0075] In certain preferred embodiments, the substitutions described in any of the above are conservative substitutions.
[0076] In certain embodiments, the antibody or antigen-binding fragment thereof is humanized. Example 3 provides the basic process of the humanization strategy, and Table 3 provides the variable region amino acid sequence numbers of preferred humanized antibodies.
[0077] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as shown in SEQ ID NO: 2, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as shown in SEQ ID NO: 3, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0078] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as shown in SEQ ID NO:4, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as shown in SEQ ID NO:5, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0079] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO:6, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as set forth in SEQ ID NO:7, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0080] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 8, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 9, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0081] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as shown in SEQ ID NO: 10, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as shown in SEQ ID NO: 11, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0082] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 12, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 13, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0083] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 14, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 15, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0084] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 16, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 17, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0085] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 18, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 19, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0086] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 20, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 21, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0087] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 22, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 23, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0088] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 24, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 25, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0089] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 26, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 27, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0090] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 28, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 29, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0091] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 30, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 31, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0092] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 32, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 33, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0093] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 34, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 35, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0094] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 36, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 37, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0095] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 38, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 39, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0096] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO:40, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO:41, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0097] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 42, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 43, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0098] In certain preferred embodiments, the humanized antibody or antigen-binding fragment thereof comprises the following VH and VL sequences: the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 44, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and the VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 45, or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)).
[0099] In certain embodiments, the antibody or antigen-binding fragment is a full-length antibody, Fab, Fab', (Fab')2, Fd, Fv, dAb, scFv, or scFv-scFv.
[0100] In certain embodiments, the antibody comprises a heavy chain constant region and a light chain constant region derived from a human immunoglobulin.
[0101] More preferably, the antibody comprises the amino acid sequence of the human kappa light chain constant region.
[0102] More preferably, the antibody comprises a heavy chain constant region selected from human IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD and IgE; more preferably, it comprises a heavy chain constant region selected from human IgG1, IgG2 and IgG4; and, the heavy chain constant region has a native sequence or a sequence having one or more amino acid substitutions, deletions or additions compared to the native sequence from which it is derived.
[0103] Preferably, the antibody comprises a heavy chain constant region of human IgG4, and the heavy chain constant region contains an amino acid mutation of S228P.
[0104] In any of the above embodiments, the antibodies or antigen-binding fragments thereof of the present invention are capable of binding to D Binds to TFPI, preferably with a K of 1 nM or lower D Binds to TFPI; preferably, with a K of 100 pM or less D Binds to TFPI; more preferably, with a K of 10 pM or less D Binds to TFPI.
[0105] In one aspect, the present invention provides a bispecific antibody or antigen-binding portion thereof, comprising the above-described antibody or antigen-binding portion thereof linked to a second antibody or antigen-binding portion thereof, wherein the second antibody or antigen-binding portion thereof binds to tissue factor pathway inhibitor.
[0106] In one aspect of the present invention, a DNA molecule encoding the above-mentioned antibody or antigen-binding fragment thereof is provided.
[0107] One aspect of the present invention provides a vector comprising the above-mentioned DNA molecule.
[0108] In one aspect of the present invention, a host cell comprising the above-mentioned vector is provided; the host cell comprises a prokaryotic cell, a yeast or a mammalian cell, such as a CHO cell, a NS0 cell or other mammalian cell, preferably a CHO cell.
[0109] One aspect of the present invention provides a pharmaceutical composition comprising the above-mentioned antibody or antigen-binding fragment thereof and a pharmaceutically acceptable excipient, carrier or diluent.
[0110] In certain embodiments, the pharmaceutical composition can be administered to a patient by subcutaneous injection. For example, a dose of 1 to 500 mg of an anti-TFPI antibody can be administered to a patient by subcutaneous injection once a day, once every 2 days, once every 3 days, once every 4 days, once every 5 days, once every 6 days, twice a week, once a week, once every two weeks, or once a month.
[0111] One aspect of the present invention provides the use of the antibody or its antigen-binding fragment in the preparation of a medicament for preventing or treating a disease or event caused by a genetic or acquired coagulation factor deficiency. For example, the antibody or its antigen-binding fragment provided by the present invention can be used to prevent the interaction between TFPI and FXa, or to prevent TFPI-dependent inhibition of TF / FVIIa activity. In addition, the antibody can also be used to restore TF / FVIIa-driven FXa production to avoid insufficient FXa amplification that is dependent on FVIII or FIX. Furthermore, the diseases include hemophilia A and hemophilia B, as well as spontaneous bleeding events, traumatic bleeding events, or bleeding events that occur during surgical prevention, perioperative management, or surgical treatment in hemophilia patients.
[0112] Another aspect of the present invention provides a method for preventing or treating diseases or bleeding events caused by hereditary or acquired coagulation factor deficiency, which comprises administering an effective amount of the antibody or antigen-binding fragment thereof of the present invention, or the pharmaceutical composition of the present invention.
[0113] One aspect of the present invention provides the use of the antibody or antigen-binding fragment thereof in the preparation of a medicament for preventing or treating a hereditary coagulation disorder. Preferably, the hereditary coagulation disorder is platelet asthenia and giant platelet syndrome.
[0114] The technical solution provided by the present invention has achieved beneficial effects, which are summarized as follows:
[0115] 1. The TFPI antibody provided by the present invention has good binding affinity, can specifically recognize human TFPI, and is effective in treating and preventing hemophilia, and has been initially clinically validated;
[0116] 2. The TFPI antibody provided herein does not directly interact with the key amino acid R107 of the K2 domain of the TFPI protein. Instead, it directly binds to the adjacent Y109, shielding the nearby R107 site. The R107 amino acid in the K2 domain is directly involved in inhibiting the coagulation factor FXa and is located at the center of the active region. Simulations of the AB8D / TFPI K2 and FXa / TFPI K2 complexes show that upon superposition with the common TFPI K2, the AB8D antibody interacts with or sterically hinders the coagulation factor FXa, indicating that AB8D competes with FXa for binding to TFPI K2. Due to the high affinity of the AB8D antibody, it blocks the binding between TFPI K2 and coagulation factor FXa via Y109 adjacent to R107. Within the effective dose range, the coagulation cascade reaction is less likely to be amplified, reducing the risk of thrombosis and thus offering a higher safety profile.
[0117] 3. In preclinical safety evaluation studies such as repeated dosing toxicity tests and maximum tolerated dose tests, the TFPI antibody provided by the present invention had no significant effects on the central nervous system, cardiovascular and respiratory systems of rhesus monkeys, was non-irritating to the local area upon administration, and no abnormal changes in the immunotoxicity evaluation indicators related to the antibody of the present invention were observed. It has good safety and significant clinical value.
[0118] Abbreviations and Definitions
[0119] The following abbreviations are used herein: CDR Complementarity-Determining Region, complementarity-determining region in an immunoglobulin variable region, defined using the Kabat, IMGT, Chothia, or AbM numbering systems (see the terms "hypervariable region" or "CDR region" or "complementarity-determining region"). EC 50 Concentration that produces 50% efficacy or binding ELISA Enzyme-linked immunosorbent assay FR Antibody framework region (Framework), immunoglobulin variable region excluding CDR region HRP Horseradish peroxidase IC 50 Concentration that produces 50% inhibition IgG Immunoglobulin G Kabat Immunoglobulin amino acid sequence alignment and numbering system pioneered by Elvin A Kabat. PCR Polymerase chain reaction V region A segment of the IgG chain that varies in sequence between different antibodies. It extends to Kabat residue 109 of the light chain and residue 113 of the heavy chain. K D Equilibrium dissociation constant k a Binding rate constant k d Dissociation rate constant
[0120] Unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the cell culture, biochemistry, nucleic acid chemistry, immunology, and other laboratory procedures used herein are conventional procedures widely used in the relevant fields. To facilitate a better understanding of the present invention, definitions and explanations of relevant terms are provided below.
[0121] The term "tissue factor pathway inhibitor" or "TFPI" refers to any variants, isoforms, and species homologs of human TFPI that are naturally expressed by cells.
[0122] The term "EU Numbering System" (EU Numbering System or Scheme): Eu refers to the first human IgG1 immunoglobulin isolated and purified by Gerald M. Edelman et al. in the late 1960s (1968-1969). It was named Eu, and its amino acid sequence was determined and numbered (Edelman GM et al, 1969, Proc Natl Acad USA, 63:78-85). The amino acid sequences of other immunoglobulin heavy chain constant regions are aligned with Eu, and the corresponding amino acid positions are assigned Eu numbers. The Eu numbering system primarily applies to the immunoglobulin heavy chain constant region, including CH1, CH2, CH3, and the hinge region.
[0123] The term "Kabat Numbering System or Scheme" refers to a standardized numbering scheme for human immunoglobulin variable regions, first proposed by Kabat et al. in 1979 (Kabat EA, Wu TT, Bilofsky H, Sequences of Immunoglobulin Chains: Tabulation and Analysis of Amino Acid Sequences of Precursors, V-regions, C-regions, J-Chain and β2-Microglobulins. 1979. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health). In the book "Protein Sequences of Immunological Interest" (Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. 1991. Sequences of Proteins of Immunological Interest, 5th edition. Bethesda, MD: US Department of Health and Human Services, National Institutes for Health), Kabat et al. aligned and numbered the amino acid sequences of antibody light and heavy chains. They found that the analyzed sequences showed variable lengths, and that missing and inserted amino acids or amino acid fragments could only appear at specific positions. Interestingly, the insertion points were mostly located inside the CDR, but could also appear at certain positions in the framework region. In the Kabat numbering scheme, the light chain variable region is numbered to position 109, and the heavy chain variable region is numbered to position 113. The inserted amino acids of the light and heavy chains are identified and annotated by letters (e.g., 27a, 27b...). All Lambda light chains do not contain the residue at position 10, and Lambda and Kappa light chains are encoded by two different genes and located on different chromosomes. Lambda and Kappa light chains can be distinguished by the differences in their constant region amino acid sequences. Unlike the EU numbering system, which only targets the heavy chain constant region, the Kabat numbering system covers the full-length immunoglobulin sequence, including the variable and constant regions of the immunoglobulin light and heavy chains.
[0124] The term "antibody" generally refers to a protein binding molecule having the function of an immunoglobulin class. Typical examples of antibodies are immunoglobulins, and derivatives or functional fragments thereof, as long as they show the desired binding specificity. The technology used to prepare antibodies is well known in the art. "Antibodies" include different classes of natural immunoglobulins (e.g., IgA, IgG, IgM, IgD, and IgE) and subclasses (e.g., IgG1, IgG2, IgA1, IgA2, etc.). "Antibodies" also include non-natural immunoglobulins, including, for example, single-chain antibodies, chimeric antibodies (e.g., humanized mouse antibodies), and heterologous conjugate antibodies (e.g., bispecific antibodies), as well as antigen-binding fragments thereof (e.g., Fab', F(ab')2, Fab, Fv, and rIgG). See also, for example, Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co, Rockford, 111); Kuby J, Immunology, 3rd Ed, WH Freeman & Co, New York, 1997. Antibodies can bind to one antigen, which is called "monospecific," to two different antigens, which is called "bispecific," or to more than one different antigen, which is called "multispecific." Antibodies can be monovalent, bivalent, or multivalent, meaning they can bind to one, two, or more antigen molecules at a time. An antibody binds "monovalently" to a specific protein, meaning one molecule of the antibody binds to only one molecule of the protein, but it can also bind to different proteins. When an antibody binds only to one molecule of each of two different proteins, it binds "monovalently" to each protein, and the antibody is "bispecific" and binds "monovalently" to each of the two different proteins. Antibodies can be "monomeric," meaning they comprise a single polypeptide chain. Antibodies can comprise multiple polypeptide chains ("multimeric") or can comprise two ("dimeric"), three ("trimeric"), or four ("tetrameric") polypeptide chains. If the antibody is multimeric, the antibody can be a homomultimer, i.e., the antibody comprises more than one molecule of only one polypeptide chain, including a homodimer, homotrimer, or homotetramer. Alternatively, the multimeric antibody can be a heteromultimer, i.e., the antibody comprises more than one different polypeptide chain, including a heterodimer, heterotrimer, or heterotetramer.
[0125] The term "monoclonal antibody (mAb)" refers to an antibody obtained from a population of substantially homogeneous antibodies, e.g., the individual antibodies contained in the population are identical except for possible small amounts of mutations, such as naturally occurring mutations. Thus, the attributive "monoclonal" indicates that the antibody is characterized as not being a mixture of discrete antibodies. Monoclonal antibodies are produced by methods known to those skilled in the art, e.g., by fusing myeloma cells with immune spleen cells to prepare hybrid antibody-producing cells. They are synthesized by hybridoma culture and are not contaminated by other immunoglobulins. Monoclonal antibodies can also be obtained using, for example, recombinant techniques, phage display techniques, synthetic techniques, or other existing technologies.
[0126] The term "epitope" refers to any determinant that can be bound by an antigen binding protein, such as an antibody or T cell receptor. An epitope is a region of an antigen that is bound by an antigen binding protein that targets the antigen, and when the antigen is a protein, the epitope includes specific amino acids that directly contact the antigen binding protein. Most commonly, epitopes are located on proteins, but in some cases can be located on other types of molecules, such as nucleic acids. Epitope determinants can include chemically active surface groups of molecules, such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and can have specific three-dimensional structural characteristics and / or specific charge characteristics. Typically, antibodies specific for a particular target antigen will preferentially recognize epitopes on the target antigen in a complex mixture of proteins and / or macromolecules. Epitopes can be composed of continuous sequences (protein primary structure) or discontinuous protein three-dimensional structures. Antigenic determinants are mostly present on the surface of antigenic substances. A natural antigenic substance can have multiple and multiple determinants. The larger the antigen molecule, the greater the number of determinants.
[0127] The term "binding" refers to the microscopic binding of an antibody or antigen-binding fragment thereof to its corresponding target, which can generally be viewed as interaction and / or blocking between the corresponding amino acid residues at a distance of 5 angstroms or less. The forces contributing to the interaction and / or blocking may include hydrogen bonds, van der Waals forces, electrostatic forces, cation-aromatic ring π bonds, and / or hydrophobic forces.
[0128] An antibody that "preferentially binds" or "specifically binds" (used interchangeably herein) to an epitope is a term well known in the art, and methods of determining such specific or preferred binding are also well known in the art. A molecule is said to exhibit "specific binding" or "preferential binding" if it reacts or binds to a particular cell or substance more frequently, more rapidly, with a longer duration and / or greater affinity than it reacts or binds to alternative cells or substances. An antibody "specifically binds" or "preferentially binds" to a target if it binds to the target with greater affinity, avidity, more readily, and / or for a longer duration than it binds to other substances. In addition, an antibody "specifically binds" or "preferentially binds" to a target if it binds to the target in a sample with greater affinity, avidity, more readily, and / or for a longer duration than it binds to other substances present in the sample. For example, an antibody that specifically binds or preferentially binds to a TFPI epitope is one that binds to that epitope with greater affinity, avidity, greater readiness, and / or greater duration than it binds to other TFPI epitopes or non-TFPI epitopes. It is also understood by reading this definition that, for example, an antibody (or portion or epitope) that "specifically binds" or "preferentially binds" to a first target may or may not specifically bind to or preferentially bind to a second target. Thus, "specifically binds" or "preferentially binds" does not necessarily require (although it can include) exclusive binding. Generally, but not necessarily, reference to binding means preferential binding. "Specifically binds" or "preferentially binds" includes compounds, such as proteins, nucleic acids, antibodies, etc., that recognize and bind to a specific molecule in a sample but do not substantially recognize or bind to other molecules. For example, an antibody or peptide receptor that recognizes and binds to a cognate ligand or binding partner in a sample (e.g., an anti-TFPI antibody that binds TFPI) but does not substantially recognize or bind to other molecules in the sample specifically binds to that cognate ligand or binding partner. Thus, under specified assay conditions, the particular binding moiety (e.g., an antibody or antigen binding portion thereof or a receptor or ligand binding portion thereof) preferentially binds a specific target molecule and does not bind in significant amounts to other components present in the test sample.
[0129] The term "pKa" refers to the negative logarithm of the acid dissociation constant of an acidic substance. The pKa value is obtained by taking the negative logarithm of the acid dissociation constant Ka value to the base 10, that is, pKa = -log10(Ka). It is an indicator used to measure the strength of an acid. The smaller the pKa value, the stronger the acid; the larger the pKa value, the weaker the acid. The acid dissociation constant (Ka) refers to the time it takes for an acid to dissociate in water to form hydrogen ions (H + ) and the corresponding anion (A - ) is the equilibrium constant of the reaction. A larger Ka value indicates a stronger acid, that is, a higher degree of acid dissociation. Ka=[H + ][A - ] / [HA], the above is the ionization equilibrium equation of acid HA, [HA], [H + ] and [A - ], respectively acid HA, hydrogen ion H + , and acid radical A - concentration.
[0130] The term "antibody fragment" or "antigen-binding fragment" refers to an antigen-binding fragment of an antibody and an antibody analog that retains the ability to specifically bind to an antigen, and generally includes at least a portion of the antigen-binding region or variable region of the parent antibody. Antibody fragments retain at least some of the binding specificity of the parent antibody. Generally, when expressed in molar units (K D ) is used to represent activity, the antibody fragment retains at least 10% of the parent antibody's binding activity. Preferably, the antibody fragment retains at least 20%, 50%, 70%, 80%, 90%, 95% or 100% of the parent antibody's binding affinity for the target. Antibody fragments include, but are not limited to, Fab fragments, Fab' fragments, F(ab')2 fragments, Fv fragments, Fd fragments, complementarity determining region (CDR) fragments, disulfide bond stabilized proteins (dsFv), etc.; linear antibodies (Linear Antibody), single-chain antibodies (e.g., scFv single antibodies), single antibodies (Unibody, technology from Genmab), bivalent single-chain antibodies, single-chain phage antibodies, single-domain antibodies (e.g., VH domain antibodies), domain antibodies (Domantis, technology from Domantis), nanobodies (nanobodies, technology from Ablynx); multispecific antibodies formed by antibody fragments (e.g., three-chain antibodies, four-chain antibodies, etc.); and engineered antibodies such as chimeric antibodies (e.g., humanized murine antibodies), heteroconjugate antibodies, etc. These antibody fragments are obtained using conventional techniques known to those skilled in the art, and the utility of these fragments is screened using the same methods as for intact antibodies.
[0131] The term "single-chain Fv antibody" (or "scFv antibody") refers to an antibody fragment comprising the VH and VL domains of an antibody. It is a recombinant protein of a heavy chain variable region (VH) and a light chain variable region (VL) connected by a linker. The linker allows the two domains to cross-link to form an antigen binding site. The linker sequence is generally composed of a flexible peptide, such as, but not limited to, G2(GGGGS)3. The size of scFv is generally 1 / 6 of a complete antibody. A single-chain antibody is preferably an amino acid chain sequence encoded by a nucleotide chain. For a review of scFv, see Pluckthun A, 1994. Antibodies from Escherichia coli, in The Pharmacology of Monoclonal Antibodies, Vol 113, Rosenberg M and Moore GP (EDs.), Springer-Verlag, New York, pp 269-315. See also International Patent Application Publication No. WO 88 / 01649 and U.S. Patent Nos. 4,946,778 and 5,260,203.
[0132] The term "VL domain" refers to the amino-terminal variable region domain of an immunoglobulin light chain.
[0133] The term "VH domain" refers to the amino-terminal variable region domain of an immunoglobulin heavy chain.
[0134] The term "hinge region" includes that portion of the heavy chain molecule that connects the CH1 domain to the CH2 domain. The hinge region comprises approximately 25 residues and is flexible, allowing the two N-terminal antigen-binding regions to move independently. The hinge region can be divided into three distinct domains: the upper, middle, and lower hinge domains (Roux KH et al, 1998, J Immunol, 161: 4083-4090).
[0135] The term "Fv region" comprises the variable regions from both the heavy and light chains, but lacks the constant regions, and is the minimum fragment that contains a complete antigen recognition and binding site.
[0136] The term "heavy chain constant region" includes amino acid sequences from immunoglobulin heavy chains. The polypeptide comprising the heavy chain constant region includes at least one of the following: a CH1 domain, a hinge (e.g., an upper hinge region, a middle hinge region, and / or a lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment thereof. For example, the antigen-binding polypeptide used in the present application may include a polypeptide chain having a CH1 domain; a polypeptide having a CH1 domain, at least a portion of a hinge domain, and a CH2 domain; a polypeptide chain having a CH1 domain and a CH3 domain; a polypeptide chain having a CH1 domain, at least a portion of a hinge domain, and a CH3 domain, or a polypeptide chain having a CH1 domain, at least a portion of a hinge structure, a CH2 domain, and a CH3 domain. In another embodiment, the polypeptide of the present application includes a polypeptide chain having a CH3 domain. In addition, the antibody used in the present application may lack at least a portion of a CH2 domain (e.g., all or a portion of a CH2 domain). As described above, but as will be understood by those of ordinary skill in the art, the heavy chain constant regions may be modified such that they differ in amino acid sequence from naturally occurring immunoglobulin molecules.
[0137] The term "light chain constant region" includes an amino acid sequence from an antibody light chain. Preferably, the light chain constant region includes at least one of a constant kappa domain and a constant lambda domain.
[0138] The term "Fc region" or "Fc fragment" refers to the C-terminal region of an immunoglobulin heavy chain, which contains at least a portion of the hinge region, the CH2 domain, and the CH3 domain, and mediates the binding of the immunoglobulin to host tissues or factors, including binding to Fc receptors on various cells of the immune system (e.g., effector cells) or binding to the first component (C1q) of the classical complement system. Fc regions include native sequence Fc regions and variant Fc regions.
[0139] Typically, the human IgG heavy chain Fc region is the segment from the amino acid residue at position Cys 226 or Pro 230 to the carboxyl terminus, but its boundaries may vary. The C-terminal lysine (residue 447, according to the EU numbering system) of the Fc region may or may not be present. Fc can also refer to this region in an independent state, or in the context of a protein polypeptide comprising an Fc region, such as a "binding protein comprising an Fc region," also referred to as an "Fc fusion protein" (e.g., an antibody or immunoadhesin). The native sequence Fc region in the antibodies of the present invention is derived from, including mammalian (e.g., human) IgG1, IgG2 (IgG2A, IgG2B), IgG3, and IgG4. In certain embodiments, relative to the mammalian Fc polypeptide amino acid sequence, the amino acid sequences of the two Fc polypeptide chains have single amino acid substitutions, insertions, and / or deletions of approximately 10 amino acids per 100 amino acids. In some embodiments, the amino acid differences in the Fc region can be Fc alterations that extend half-life, alterations that increase FcRn binding, alterations that enhance Fcγ receptor (FcγR) binding, and / or alterations that enhance ADCC, ADCP, and / or CDC.
[0140] As used herein, the term "immune response" refers to the action of immune cells (e.g., lymphocytes, antigen-presenting cells, phagocytes, or granulocytes) and soluble macromolecules (including antibodies, cytokines, and complement) produced by immune cells or the liver, which results in selective damage, destruction, or removal from the human body of invasive pathogens, cells or tissues infected by pathogens, cancer cells, or normal human cells or tissues in the context of autoimmunity or pathological inflammation. In the present invention, the term "antigen-specific T cell response" refers to an immune response generated by a T cell that occurs when the T cell is stimulated by an antigen to which the T cell is specific. Non-limiting examples of responses generated by T cells upon antigen-specific stimulation include proliferation of T cells and production of cytokines (e.g., IL-2).
[0141] As used herein, the term "antibody-dependent cell-mediated cytotoxicity (ADCC)" refers to a form of cytotoxicity in which Ig binds to Fc receptors (FcRs) present on cytotoxic cells (e.g., natural killer (NK) cells, neutrophils, or macrophages), causing these cytotoxic effector cells to specifically bind to antigen-attached target cells and then kill the target cells by secreting cytotoxins. Methods for detecting the ADCC activity of antibodies are known in the art and can be evaluated, for example, by measuring the binding activity between the test antibody and an Fc receptor (e.g., CD16a).
[0142] As used herein, the term "complement-dependent cytotoxicity (CDC)" refers to a form of cytotoxicity in which the complement cascade is activated by binding of the complement component C1q to the Fc receptor of an antibody. Methods for detecting the CDC activity of an antibody are known in the art and can be evaluated, for example, by measuring the binding activity between the test antibody and an Fc receptor (e.g., C1q).
[0143] In IgG, IgA, and IgD antibody isotypes, the Fc region comprises the CH2 and CH3 constant domains of each of the antibody's two heavy chains; IgM and IgE Fc regions comprise three heavy chain constant domains (CH2-4 domains) in each polypeptide chain.
[0144] The term "humanized antibody" refers to a non-human antibody that has been genetically engineered and whose amino acid sequence has been modified to increase sequence homology with a human antibody. Most or all amino acids outside the CDR domain of a non-human antibody, such as a mouse antibody, are replaced with corresponding amino acids from a human immunoglobulin, while most or all amino acids within one or more CDR regions remain unchanged. Amino acid additions, deletions, insertions, substitutions, or modifications are permitted as long as they do not eliminate the antibody's ability to bind a specific antigen. "Humanized" antibodies retain antigenic specificity similar to that of the original antibody. The source of the CDRs is not particularly limited and can be derived from any animal. For example, CDR regions derived from mouse antibodies, rat antibodies, rabbit antibodies, or non-human primate antibodies (e.g., cynomolgus macaques) can be utilized. Framework regions can be obtained by searching the IMGT antibody germline database (http: / / www.imgt.org / 3Dstructure-DB / cgi / DomainGapAlign.cgi). Generally, human germline antibody sequences with high homology to the engineered non-human antibody are selected as framework regions for the humanized antibody.
[0145] The term "hypervariable region" or "CDR region" or "complementarity determining region" refers to the amino acid residues of an antibody that are responsible for antigen binding and is a non-contiguous amino acid sequence. The CDR region sequence can be defined by the methods of Kabat, Chothia, IMGT (Lefrance et al, 2003, Dev Comparat Immunol, 27: 55-77) or any other CDR region sequence determination method known in the art to identify amino acid residues within the variable region. For example, the hypervariable region comprises the following amino acid residues: amino acid residues from the "complementarity determining region" or "CDR" as defined by sequence alignment (Kabat numbering system), e.g., residues 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3) of the light chain variable domain and residues 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3) of the heavy chain variable domain, see Kabat et al, 1991, Sequences of Proteins of Immunological Interest, 5th Edition, Public Health Service, National Institutes of Health. Health, Bethesda, Md.; and / or residues from the structurally defined "hypervariable loops" (HVL) (Chothia numbering system), e.g., residues 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3) of the light chain variable domain and residues 26-32 (HCDR1), 53-55 (HCDR2), and 96-101 (HCDR3) of the heavy chain variable domain, see Chothia C and Lesk AM, 1987, J Mol Biol, 196:901-917; Chothia C et al, 1989, Nature, 342:878-883. "Framework" residues or "FR" residues are variable domain residues other than the hypervariable region residues as defined herein. In certain embodiments, the CDRs contained in the antibodies or antigen-binding fragments thereof of the invention are preferably identified by the Kabat or IMGT numbering systems. Those skilled in the art can clearly assign each numbering system to any variable domain sequence without relying on any experimental data beyond the sequence itself. For example, the Kabat residue numbering scheme for a given antibody can be determined by comparing the antibody sequence with the homology regions of each "standard" numbering sequence. Based on the sequence numbering scheme provided herein, it is well within the routine skills of those skilled in the art to determine the numbering of any variable region sequence in the sequence listing.
[0146] As used herein, the term "isolated" with respect to nucleic acids (e.g., DNA or RNA) refers to molecules that are separated from other macromolecules present in nature, such as DNA or RNA, respectively. As used herein, the term "isolated" also refers to nucleic acids or polypeptides that are substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA technology, or that are substantially free of chemical precursors or other chemicals when prepared by chemical synthesis. In addition, "isolated nucleic acid" refers to nucleic acid fragments that are not naturally occurring fragments and are not found in nature. The term "isolated" is also used herein to refer to cells or polypeptides that are separated from other cellular proteins or tissues. Isolated polypeptides are meant to include purified and recombinant polypeptides.
[0147] The term "cross-reactivity" refers to the ability of an antibody described herein to bind to antigens from different species. Cross-reactivity can be measured by detecting specific reactivity with purified antigens in binding assays (e.g., SPR, ELISA), or binding to cells that physiologically express the antigen or otherwise interacting with the function of cells that physiologically express the antigen. Examples of assays known in the art for determining binding affinity include surface plasmon resonance (e.g., Biacore) or similar techniques (e.g., Kinexa or Octet).
[0148] The terms "immunobinding" and "immunobinding property" refer to a non-covalent interaction that occurs between an immunoglobulin molecule and an antigen for which the immunoglobulin is specific. The strength or affinity of the immunobinding interaction can be measured by the equilibrium dissociation constant (K) of the interaction. D ) indicates that K D The smaller the value, the higher the affinity. The immunological binding properties of the selected polypeptide can be determined using methods well known in the art. One assay involves measuring the speed of formation and dissociation of the antigen / antibody complex. Both the "association rate constant" (ka or kon) and the "dissociation rate constant" (kd or koff) can be calculated by the concentration and the actual rate of association and dissociation (see Malmqvist M, 1993, Nature, 361: 186-187). The ratio of ka / kd is equal to the equilibrium dissociation constant K D (See Davies DR et al, 1990, Annual Rev Biochem, 59: 439-473). K can be measured by any effective method. D , ka and kd values.
[0149] The term "host cell" refers to a cell in which a vector can be propagated and its DNA can be expressed, and the cell can be a prokaryotic cell or a eukaryotic cell. The term also includes any progeny of the subject host cell. It should be understood that not all progeny are identical to the parent cell, as mutations may occur during the replication process, and such progeny are included. Host cells include prokaryotic cells, yeast, or mammalian cells, such as CHO cells, NSO cells, or other mammalian cells.
[0150] The term "identity" is used to refer to the matching of sequences between two polypeptides or between two nucleic acids. When a certain position in the two sequences being compared is occupied by the same base or amino acid monomer subunit (for example, a certain position in each of the two DNA molecules is occupied by adenine, or a certain position in each of the two polypeptides is occupied by lysine), then the molecules are identical at that position. The "percent identity" between two sequences is a function of the number of matching positions shared by the two sequences divided by the number of positions compared × 100. For example, if 6 out of 10 positions of the two sequences match, then the two sequences have 60% identity. For example, the DNA sequences CTGACT and CAGGTT have a total of 50% identity (3 out of a total of 6 positions match). Typically, comparisons are made when the two sequences are aligned to produce maximum identity. Such an alignment can be conveniently performed by computer programs such as the Align program (DNAstar, Inc.) using the method of Needleman and Wunsch (Needleman SB and Wunsch CD, 1970, J Mol Biol, 48:443-453).
[0151] The terms "mutated," "mutant," and "mutation" refer to a substitution, deletion, or insertion of one or more nucleotides or amino acids, respectively, compared to a native nucleic acid or polypeptide (ie, a reference sequence that can be used to define the wild-type sequence).
[0152] The term "conservative modification" is intended to mean that the amino acid modification does not significantly affect or change the binding characteristics of the antibody containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into the antibodies of the present invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions refer to the replacement of an amino acid residue with an amino acid residue having a similar side chain. Families of amino acid residues with similar side chains have been described in detail in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), β-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues in the CDR regions of an antibody of the invention can be replaced with other amino acid residues from the same side chain family.
[0153] The antibodies of the present invention or nucleic acids or polynucleotides encoding the antibodies of the present application can be used to prepare pharmaceutical compositions or sterile compositions, for example, by mixing the antibodies with pharmaceutically acceptable carriers, excipients or stabilizers. Pharmaceutical compositions may include one or a combination (e.g., two or more different) of the antibodies of the present invention. For example, the pharmaceutical compositions of the present invention may include a combination of antibodies or antibody fragments (or immunoconjugates) with complementary activities that bind to different epitopes on the target antigen. The formulations of therapeutic and diagnostic agents can be prepared by mixing with pharmaceutically acceptable carriers, excipients or stabilizers in the form of, for example, lyophilized powders, slurries, aqueous solutions or suspensions. The term "pharmaceutically acceptable" means that when the molecule itself, molecule fragment or composition is appropriately administered to an animal or human, they will not produce adverse, allergic or other adverse reactions. Specific examples of some substances that can be used as pharmaceutically acceptable carriers or their components include sugars (e.g., lactose), starch, cellulose and its derivatives, vegetable oils, gelatin, polyols (e.g., propylene glycol), alginic acid, etc. The antibodies of the present invention or nucleic acids or polynucleotides encoding the antibodies of the present application can be used alone or in combination with one or more other therapeutic agents, such as vaccines.
[0154] The term "pharmaceutically acceptable carriers and / or excipients and / or stabilizers" refers to carriers and / or excipients and / or stabilizers that are pharmacologically and / or physiologically compatible with the subject and the active ingredient, and are non-toxic to the cells or mammals to which they are exposed at the dosages and concentrations employed. These include, but are not limited to, pH adjusters, surfactants, adjuvants, ionic strength enhancers, diluents, agents that maintain osmotic pressure, agents that delay absorption, and preservatives. For example, pH adjusters include, but are not limited to, phosphate buffers. Surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, such as Tween-80. Ionic strength enhancers include, but are not limited to, sodium chloride. Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, and sorbic acid. Agents that maintain osmotic pressure include, but are not limited to, sugars, NaCl, and their analogs. Agents that delay absorption include, but are not limited to, monostearate and gelatin. Diluents include, but are not limited to, water, aqueous buffers (such as buffered saline), alcohols, and polyols (such as glycerol). Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as thimerosal, 2-phenoxyethanol, parabens, chlorobutanol, phenol, sorbic acid, etc. Stabilizers have the meanings generally understood by those skilled in the art, and are capable of stabilizing the desired activity of the active ingredient in the drug, including, but not limited to, sodium glutamate, gelatin, SPGA, sugars (such as sorbitol, mannitol, starch, sucrose, lactose, dextran, or glucose), amino acids (such as glutamic acid, glycine), proteins (such as dried whey, albumin, or casein), or degradation products thereof (such as lactalbumin hydrolysate), etc.
[0155] As used herein, the term "effective amount" refers to an amount sufficient to achieve, or at least partially achieve, a desired effect. For example, a prophylactic effective amount is an amount sufficient to prevent, arrest, or delay the onset of a disease; a therapeutic effective amount is an amount sufficient to cure or at least partially arrest the disease and its complications in a patient already suffering from the disease. Determining such an effective amount is well within the capabilities of those skilled in the art. For example, an effective amount for therapeutic use will depend on the severity of the disease being treated, the overall state of the patient's own immune system, the patient's general condition such as age, weight, and sex, the mode of administration of the drug, and any other concurrently administered treatments.
[0156] The embodiments of the present invention are further described by the following examples. However, it should be understood by those skilled in the art that the following figures and examples are only used to illustrate the present invention, rather than to further limit the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0157] Figure 1. Human TFPI binding ELISA of antibody AB8D, Novo Nordisk antibody Concizumab, and Pfizer antibody Marstacimab.
[0158] Figure 2-1. Antibody AB8D, Novo Nordisk's antibody Concizumab, and Pfizer's antibody Marstacimab compete with AB8D-HRP for binding to human TFPI.
[0159] Figure 2-2. Antibody AB8D, Novo Nordisk's antibody Concizumab, and Pfizer's antibody Marstacimab compete with Concizumab-HRP for binding to human TFPI.
[0160] Figure 3. Schematic representation of the TFPI K2 binding domains of antibodies AB8D, Novo Nordisk's concizumab, and Pfizer's marstacimab. The structures of the AB8D / TFPI K2 and marstacimab / TFPI K2 complexes were predicted using alphafold modeling. The concizumab / TFPI K2 structure was obtained from the Protein Data Bank, PDB 4DTG.
[0161] Figure 4. Schematic diagram of the superposition of simulated structures of antibody AB8D, Novo Nordisk's Concizumab, and Pfizer's Marstacimab binding to the TFPI K2 domain. The three structures were superimposed through the common TFPI K2 domain.
[0162] Figure 5. Schematic representation of the superimposition of the simulated structures of antibody AB8D and coagulation factor FXa bound to the TFPI K2 domain. The structures of the AB8D / TFPI K2 and FXa / TFPI K2 complexes are superimposed through the shared TFPI K2 domain. TFPI K2 domain residues R107, Y109, and R124 are shown in a space-filling model.
[0163] Figure 6. Schematic representation of the superimposition of the simulated structures of the antibody concizumab and the coagulation factor FXa bound to the TFPI K2 domain. The structures of the concizumab / TFPI K2 and FXa / TFPI K2 complexes are superimposed through the shared TFPI K2 domain. TFPI K2 domain residues R107 and Y109 are shown in a space-filling model.
[0164] Figure 7. Schematic representation of the superimposition of simulated structures of the antibody marstacimab and coagulation factor FXa bound to the TFPI K2 domain. The marstacimab / TFPI K2 and FXa / TFPI K2 complexes are superimposed through their shared TFPI K2 domain. TFPI K2 domain residues R107, Y109, and L131 are shown in a space-filling model.
[0165] Figure 8. Schematic diagram of the structure of antibody AB8D binding to the TFPI K2 domain. Antibody heavy chain residues E50 and H35, and TFPI K2 domain residue R124 are shown in a space-filling model. DETAILED DESCRIPTION
[0166] The invention will now be described with reference to the following examples which are intended to illustrate the invention but not to limit it.
[0167] Unless otherwise specified, the molecular biology experimental methods and immunoassays used in the present invention are basically based on the methods described in J. Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, 1989, and F.M. Ausubel et al., Molecular Biology: A Laboratory Manual, 3rd edition, John Wiley & Sons, Inc., 1995. Restriction endonucleases were used according to the conditions recommended by the product manufacturers. It will be appreciated by those skilled in the art that the examples illustrate the present invention by way of example and are not intended to limit the scope of the present invention.
[0168] Example 1. Preparation of anti-human TFPI mouse monoclonal antibody
[0169] Human TFPI antigen (protein sequence: NCBI sequence number NP_006278.1) 50 μg / mouse was fully emulsified with complete Freund's adjuvant and immunized with male Balb / C mice using a multi-point immunization method. The immunization cycle was once every three weeks. On the 10th day after the third immunization, blood was collected through the tail vein and the plasma anti-human TFPI antibody titer was tested by ELISA to monitor the degree of mouse immune response. Then, 3 days before fusion, the mouse with the highest anti-human TFPI antibody titer was boosted once. After 3 days, the mouse was sacrificed and the spleen of the mouse was removed and fused with the mouse myeloma Sp2 / 0 cell line. Mix 2×10 8 Sp2 / 0 cells and 2×10 8 Splenocytes were fused in 50% polyethylene glycol (molecular weight 1450) and 5% dimethyl sulfoxide (DMSO) solution. The number of spleen cells was adjusted to 5 × 10 cells / mL using Iscove's medium (containing 10% fetal bovine serum, 100 U / mL penicillin, 100 μg / mL streptomycin, 0.1 mM hypoxanthine, 0.4 μM aminopterin, and 16 μg thymidine). 5 / mL, 0.3mL was added to the wells of a 96-well culture plate and placed in a 37°C, 5% CO2 incubator. After 10 days of culture, the supernatant was assayed for clones with antibodies that showed high affinity binding to TFPI using a high-throughput ELISA assay. The fused cells expressing the monoclonal antibody were then subcloned and further screened to obtain hybridoma cell line #3-71.
[0170] The clones producing specific antibodies were cultured in RPMI 1640 medium supplemented with 10% FCS. When the cell density reached approximately 5 × 10 5 When the culture medium reached 10 cells / mL, the culture medium was replaced with serum-free medium. After 2 to 4 days, the culture medium was centrifuged to collect the culture supernatant. The antibody was purified using a protein G column. The monoclonal antibody eluate was dialyzed against 150 mM NaCl. The dialyzed solution was sterilized by filtration through a 0.22 μm filter to obtain the purified anti-human TFPI murine monoclonal antibody mAb3-71 to be tested.
[0171] Example 2: Affinity determination and kinetic study of TFPI mouse antibody
[0172] The binding affinity constant of purified anti-human TFPI mouse monoclonal antibody mAb3-71 to human TFPI was determined using bio-thin film interferometry (BLI) on a PALL ForteBio Octet RED&QK system. The multi-channel parallel quantitative analysis concentration gradient was set at 3.125, 6.25, 12.5, 25, 50, and 100 nM, with His-tagged human TFPI at 10 μg / mL coupled to a Ni-NTA sensor. The affinity determination results are shown in Table 1, which show that the mouse monoclonal antibody has an extremely high binding affinity for human TFPI, with a K of 1. D Values can reach 10 -12 M order of magnitude.
[0173] Table 1. Affinity determination results of mouse monoclonal antibodies
[0174] Example 3: Humanization of anti-human TFPI mouse antibody
[0175] The CDR grafting method is used to humanize mouse antibodies. The basic principle of CDR grafting is to transplant the CDR region of the mouse antibody onto the human antibody template, and at the same time introduce several or some key mouse antibody FR region residues that stabilize the CDR conformation and are important for antigen-antibody binding into the human antibody template (backmutations), thereby achieving the purpose of reducing the immunogenicity of the mouse antibody while maintaining the affinity of the mouse antibody. In addition to the above-mentioned CDR grafting operation, we further calculate the isoelectric point (PI), hydrophobic aggregation, post-translational modification (PTM, such as glycosylation, cleavage, isomerization sites, etc.) and immunogenicity of the humanized antibody after CDR grafting, and mutate the amino acids that cause these four problems so that the humanized antibody can fully exert its efficacy in clinical use.
[0176] The specific process of antibody humanization is as follows. Search the human antibody germline database to obtain a human antibody template with high similarity to the mouse antibody. Annotate the CDR regions of the mouse antibody and human antibody templates, and define the CDR regions according to the Kabat or IMGT scheme. Replace the six CDR regions of the human antibody template with the six CDR regions of the mouse antibody. Each of the six transplanted CDR regions can be an amino acid region defined by Kabat, or an amino acid region defined by IMGT. After the CDR transplantation, a back mutation is performed from the mouse antibody to the humanized template FR region. The key mouse antibody FR region amino acids that stabilize the conformation of the antibody CDR region and are important for antigen-antibody binding include four types of amino acid residues: 1) CDR region amino acids buried under the surface of the antibody; 2) CDR region 1) amino acids exposed on the surface of the antibody within 300kDa; 2) amino acids at the interface between the light and heavy chain domains of the antibody; and 3) vernier zone residues that stabilize the conformation of the antibody CDR region (Foote J and Winter G, 1992, J Mol Biol, 224: 487-499). The above four types of key mouse antibody FR region residues were determined by establishing a mouse antibody three-dimensional structure model. For these four types of amino acids in the human template that are inconsistent with the mouse antibody sequence, the three-dimensional structure analysis is used to select amino acids that are important for maintaining the CDR conformation and antigen-antibody binding, and amino acid transplantation or replacement is performed from the mouse antibody to the human template. Then, the isoelectric point, hydrophobic aggregation, post-translational modification and immunogenicity of the humanized antibody produced after the four types of amino acid transplantation are further calculated, and the problematic amino acids are mutated to obtain the final humanized antibody sequence.
[0177] According to the above method, a humanized antibody was constructed based on the CDR of the murine antibody mAb3-71. The amino acid sequences of the CDR regions contained in the relevant antibody variable regions are shown in Table 2, and the amino acid sequences of the heavy and light chain variable regions are shown in Table 3.
[0178] Table 2. CDR region sequences of exemplary anti-TFPI humanized antibodies
[0179] Table 3. Amino acid sequences of humanized antibody variable regions
[0180] To obtain a full-length antibody sequence consisting of two heavy chains and two light chains, the VH and VL sequences shown in Table 3 can be spliced or assembled with the antibody heavy chain constant region (preferably from human IgG1, IgG2, or IgG4) and light chain constant region (preferably from a human kappa light chain) sequences using conventional techniques. Preferably, the heavy chain constant region is a human wild-type heavy chain constant region or a mutant thereof. Preferably, the heavy chain constant region is that of human IgG4, and the heavy chain constant region contains the amino acid mutation S228P.
[0181] Example 4. Construction, expression, and preparation of anti-human TFPI antibody expression vector
[0182] According to the heavy chain and light chain sequences obtained in the above-described embodiment, the coding cDNA was designed and inserted into the pcDNA3.1 eukaryotic expression vector to construct a humanized expression vector. This expression vector plasmid contains the cytomegalovirus early gene promoter-enhancer required for high-level expression in mammalian cells. Simultaneously, the vector plasmid contains a selectable marker gene to confer kanamycin resistance in bacteria and G418 resistance in mammalian cells. In addition, the vector plasmid contains the dihydrofolate reductase (DHFR) gene, which can co-amplify the antibody gene and the DHFR gene with methotrexate (MTX) in suitable host cells.
[0183] The recombinant expression vector plasmid constructed above is transfected into a mammalian host cell line to express the humanized antibody. For stable high-level expression, the preferred host cell line is DHFR-deficient Chinese hamster ovary (CHO) cells (see U.S. Patent No. 4,818,679). The preferred transfection method is electroporation, but other methods can also be used, including calcium phosphate co-precipitation, lipofection, and protoplast fusion. In electroporation, a GenePulser (Bio-Rad Laboratories) set at 300V electric field and 1050μFd capacitance is added to the cuvette. 7 Each cell was suspended in 0.8 mL of PBS containing 20 μg of the expression vector plasmid. Two days after transfection, 0.2 mg / mL G418 and 200 nM MTX (Sigma) were added. To achieve higher levels of expression, the transfected antibody gene was co-amplified with the DHFR gene, which is inhibited by MTX. The transfectants were subcloned by limiting dilution and the secretion rate of each cell line was determined by ELISA to select cell lines with high levels of antibody expression. The conditioned medium of the antibody was collected and used to determine its biological activity in vitro and in vivo.
[0184] Example 5. Purification and characterization of anti-human TFPI antibodies
[0185] The purification and qualitative methods of the humanized antibody AB8D are exemplarily described in this embodiment. The cell culture supernatant is clarified by high-speed low-temperature centrifugation or deep filtration, 0.22μm sterilizing filtration, and subsequent purification by protein A affinity, anion exchange and cation exchange three-step chromatography. The specific method is as follows: the first step is to capture protein A affinity chromatography, the equilibrium liquid is PBS buffer, and the elution buffer (50mM NaAc-HAc, pH 3.7) is used for linear elution. 1M glacial acetic acid is added to adjust the pH of the protein A elution product to 3.6-3.8, and the virus is inactivated by incubation for 60 minutes at room temperature, and then 2M Tris is added to adjust the pH to 5.5 and neutralize. The intermediate purification selects anion exchange filler Q Bestarose FF to remove residual DNA, endotoxins, impurity proteins, etc., and the equilibrium liquid is 50mM NaAc-HAc, pH 5.5. The protein that flowed through the anionic medium was directly bound to the cation exchange medium Monomix HC45-SP. The cation exchange chromatography equilibration solution was 50 mM NaAc-HAc, pH 5.5, and linear elution was performed using an eluent (50 mM NaAc-HAc, 0.2 M NaCl, pH 5.5). The protein solution eluted from the cationic medium was filtered through a nanofiltration membrane, concentrated by ultrafiltration, and sterile filtered to obtain a stock solution.
[0186] The stock solution was analyzed by SEC-HPLC and SDS-PAGE electrophoresis. SEC-HPLC results showed that the purity of the main peak of the purified antibody reached over 99%. The theoretical molecular weight of the AB8D antibody is approximately 145 kDa. Under reducing conditions, SDS-PAGE electrophoresis showed that the light chain was approximately 25 kDa and the heavy chain was approximately 50 kDa, which is generally consistent with the theoretical values.
[0187] Example 6: Indirect ELISA binding test of anti-human TFPI antibodies
[0188] To compare the specific binding activity of antibody AB8D, Novo Nordisk's Concizumab, and Pfizer's Marstacimab to human TFPI, a unified concentration quantification standard (i.e., Onedrop OD280 with the IgG option) was used for all three. At the same time, the EC values of antibody AB8D, Novo Nordisk's Concizumab, and Pfizer's Marstacimab for binding to human TFPI were compared. 50 value.
[0189] Human TFPI / His (purchased from ACROBiosystem) was diluted to 0.1 μg / ml in 1× PBS buffer and added to a 96-well microtiter plate at a volume of 100 μl / well. The plate was incubated at 4°C for 16-20 hours. The PBS buffer was discarded from the 96-well plate and 200 μl / well of PBST / 1.5% BSA was added and blocked at room temperature for 1 hour. The plate was washed three times with PBST (pH 7.4, PBS containing 0.05% Tween 20). The TFPI antibody to be tested was added at 100 μl / well and incubated at room temperature for 1 hour. The plate was washed three times with PBST and 100 μl / well of a 1:5000 dilution of HRP-conjugated goat anti-human IgG secondary antibody (purchased from The Jackson Laboratory) was added and incubated at room temperature for 1 hour. The plate was washed three times with PBST and 100 μl / well of TMB was added and incubated at room temperature for 5-10 minutes. The reaction was terminated by adding 50 μl / well of 0.2 M sulfuric acid. The absorbance was read at dual wavelengths of 450 / 620 nm using a microplate reader.
[0190] Figure 1 shows that antibody AB8D, Novo Nordisk antibody Concizumab and Pfizer antibody Marstacimab can all specifically bind to human TFPI. The binding strength of Pfizer antibody Marstacimab is better, while antibody AB8D and Novo Nordisk antibody Concizumab are similar. Antibody AB8D, Novo Nordisk antibody Concizumab and Pfizer antibody Marstacimab bind to EC 50 They are: 9.28ng / ml, 6.67ng / ml and 3.74ng / ml respectively.
[0191] Example 7: Anti-human TFPI antibody competition binding assay
[0192] To compare the differences in binding epitopes of human TFPI among AB8D, Novo Nordisk's Concizumab, and Pfizer's Marstacimab, AB8D and Concizumab were labeled with HRP. Competition ELISAs were performed with AB8D-HRP and Concizumab-HRP, respectively, to determine the differences in binding of the three antibodies to the human TFPI epitope.
[0193] Human TFPI / His (purchased from ACROBiosystem) was diluted to 0.1 μg / ml in 1× PBS buffer and added to a 96-well microtiter plate at a volume of 100 μl / well. The plate was incubated at 4°C for 16-20 hours. The PBS buffer was discarded from the 96-well plate and 200 μl / well of PBST / 1.5% BSA was added and blocked at room temperature for 1 hour. After washing the plate three times with PBST (pH 7.4, PBS containing 0.05% Tween 20), the test TFPI antibody (starting at 10 μg / ml, serially diluted in a U-shaped plate) was added, along with 50 μl / well of 1:10,000 diluted AB8D-HRP or Concizumab-HRP, and incubated at room temperature for 1.0 hour. After washing the plate three times with PBST, 100 μl / well of TMB was added and incubated at room temperature for 5-10 minutes. The reaction was terminated by adding 50 μl / well of 0.2 M sulfuric acid. The absorbance was read at dual wavelengths of 450 / 620 nm using a microplate reader.
[0194] Figure 2-1 shows that Pfizer's antibody Marstacimab does not compete with AB8D-HRP, indicating that the two bind to different epitopes on human TFPI. Novo Nordisk's antibody Concizumab partially competes with AB8D-HRP, indicating that the two bind to similar epitopes on human TFPI that partially overlap but are not completely consistent.
[0195] Figure 2-2 shows that Pfizer's antibody Marstacimab does not compete with Concizumab-HRP, indicating that the two bind to different epitopes on human TFPI. AB8D partially competes with Concizumab-HRP, indicating that the two bind to similar epitopes on human TFPI that partially overlap but are not completely consistent.
[0196] Example 8. pH-dependent indirect ELISA binding assay of anti-human TFPI antibodies
[0197] (1) Indirect ELISA binding test
[0198] To compare the binding activity of antibody AB8D, Novo Nordisk's Concizumab, and Pfizer's Marstacimab to human TFPI under different pH conditions, a unified concentration quantification standard (i.e., Onedrop OD280 with the IgG option) was used for all of them. At the same time, the EC values of antibody AB8D, Novo Nordisk's Concizumab, and Pfizer's Marstacimab binding to human TFPI under different pH conditions were compared. 50 value.
[0199] Human TFPI / His (purchased from ACROBiosystem) was diluted to 0.1 μg / ml in 1× PBS buffer and added to a 96-well microtiter plate at a volume of 100 μl / well. The plate was incubated at 4°C for 16-20 hours. The PBS buffer in the 96-well plate was discarded, and 200 μl / well of PBST / 1.5% BSA was added and blocked at room temperature for 1 hour. The plate was washed three times with PBST (pH 7.4, PBS containing 0.05% Tween 20), and then 100 μl / well of the TFPI antibody to be tested (test antibodies were diluted in PBST / 1.5% BSA buffer at pH 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, or 7.4) was added and incubated at room temperature for 1.0 hour. After washing the plate three times with PBST, add 100 μl / well of a 1:5000 dilution of HRP-conjugated goat anti-human IgG secondary antibody (purchased from The Jackson Laboratory) and incubate at room temperature for 1 hour. After washing the plate three times with PBST, add 100 μl / well of TMB and incubate at room temperature for 5-10 minutes. Terminate the reaction by adding 50 μl / well of 0.2 M sulfuric acid. Read the absorbance at dual wavelengths of 450 / 620 nm using a microplate reader.
[0200] Table 4-1 shows the EC values of AB8D, Novo Nordisk antibody Concizumab, and Pfizer antibody Marstacimab binding to human TFPI under different pH conditions. 50 value.
[0201] Table 4-1. EC values of TFPI antibodies binding to human TFPI at different pH conditions 50 value
[0202] (2) Biofilm interferometry affinity test
[0203] Using Sartorius The R8 biomacromolecule interaction instrument used bio-layer interferometry (BLI) to detect the affinity of mouse monoclonal antibodies mAb3-71 and AB8D and Novo Nordisk's antibody Concizumab to human TFPI at pH 7.4 and pH 6.0, respectively, and analyzed the differences in affinity kinetics between the above antibodies and human TFPI under physiological and acidic conditions.
[0204] The AMC2 probe (Sartorius, Cat. Nos. 18-5163) was used to capture the antibody as a ligand, and recombinant human TFPI protein solutions of different concentrations of 100nM-6.25nM were prepared in pH 7.4 PBST solution (1×PBS, 0.05% Tween20) as the analyte. The binding of the antibody to human TFPI and the dissociation at pH 7.4 or pH 6.0 were observed in real time, and affinity analysis was performed separately. All measurements were performed at 30°C. Octet BLI Discovery12.2 was used to collect and save BLI signals, and then Octet Analysis studio 12.2 analysis software was used for data processing. The zero-concentration reference channel signal value was subtracted from the detection channel signal value to obtain the corrected signal curve. The affinity kinetic curve was fitted according to the Langmuir 1:1 binding model, and the association rate constant kon, dissociation rate constant koff, and affinity constant K were calculated. D The pH dependence of the antibody was evaluated by comparing the dissociation rates at pH 7.4 and pH 6.0.
[0205] Association rate constant kon, dissociation rate constant koff, affinity constant K D The values are shown in Table 4-2. The results showed that the dissociation rate of the mouse monoclonal antibody mAb3-71 at pH 6.0 was significantly lower than that at pH 7.4, indicating a clear pH dependence. The dissociation rate ratios of AB8D and Concizumab were 19.6 and 0.9, respectively, indicating that AB8D exhibited significant pH dependence.
[0206] Table 4-2. Comparison of affinity between anti-TFPI antibodies and human TFPI at pH 7.4 and pH 6.0
[0207] The binding of other humanized antibodies (Table 3) obtained in Example 3 to human TFPI and their dissociation at pH 7.4 or pH 6.0 were measured in real time using the BLI technology. The results showed that the other humanized TFPI antibodies shown in Table 3 also had pH-dependent antigen binding abilities, and their K values for TFPI at pH 6.0 / pH 7.4 were significantly higher than those at TFPI 7.4. D and / or the koff ratio is 2 or more, preferably 10 times or more.
[0208] Example 9: Determination of the Antigenic Epitope of Anti-Human TFPI Antibodies
[0209] The present invention uses alphafold version 2.3.0 to perform structural prediction or interaction binding mode prediction on a series of TFPI antigen / antibody complexes. The amino acid sequences used in alphafold modeling are the antibody light chain and heavy chain Fv region sequences and the human TFPI protein K2 domain sequence (K93-L152). The specific Linux commands are as follows: python3docker / run_docker.py --fasta_paths=multimer.fasta --max_template_date=2023-11-07 --model_preset=multimer --data_dir=$DOWNLOAD_DIR --output_dir= / home / user / absolute_path_to_the_output_dir. In the above command line, run_docker.py is the Python actual application running program of alphafold 2.3.0 version. multimer.fasta is an amino acid sequence file in antigen / antibody fasta format. 2023-11-07 is the date. All structures in the Protein Data Bank protein database before this date can be used as templates for modeling. multimer indicates that the molecule being predicted is a multimer or complex. $DOWNLOAD_DIR is the directory on disk where alphafold's built-in search database is stored. absolute_path_to_the_output_dir should be filled in with the directory where the prediction results are output or stored.
[0210] By default, alphafold uses five sets of modeling parameters, each with five prediction seeds, generating a total of 25 predicted structures. Predicted structures are scored based on the confidence level of the prediction accuracy, with higher scores indicating higher confidence levels on a scale of 0-100. Modeling results for the antibody AB8D of the present invention and TFPI K2 showed that the alphafold modeling confidence level for the AB8D / TFPI K2 complex was 86.00. The modeling confidence level for the marstacimab antibody and TFPI K2 domain was 86.69. The alphafold modeling confidence level for the complex between TFPI K2 and coagulation factor FXa was 81.24. Schematic diagrams of the modeled structures of the antibodies AB8D / TFPI K2, Concizumab / TFPI K2, and Marstacimab / TFPI K2 are shown in Figure 3. A structural overlay of the three complexes, AB8D / TFPI K2, Concizumab / TFPI K2, and Marstacimab / TFPI K2, is shown in Figure 4. The structural superpositions of the antibody AB8D / TFPI K2 complex, the antibody Concizumab / TFPI K2 complex, and the antibody Marstacimab / TFPI K2 complex with the FXa / TFPI K2 complex are shown in Figures 5-7, respectively.
[0211] Based on alphafold modeling, antibody AB8D binds to the following amino acids within 5 angstroms of the TFPI K2 domain: T139, T119, E101, Y109, I110, T111, Y113, F114, N116, Q118, Q121, C122, E123, R124, F125, K126, E138, and L140 (Table 5). Pfizer's antibody Marstacimab binds to the following amino acids within 5 angstroms of the TFPI K2 domain: D102, G104-G108, I110, R112, Y127-M134, N136, and E138. The crystal structure of Novo Nordisk's Concizumab antibody in complex with the TFPI K2 domain was obtained from the Protein Data Bank. Concizumab interacts within 5 angstroms with the following amino acids on the TFPI K2 domain: E100-P103, R107, Y109, T111, Y113-F114, N116, Q118, Q121-K126, N133, E138, and L140. Factor X binds within 5 angstroms to the following TFPI amino acids on the TFPI K2 domain: P103, I105-R112, R124, K126-L131, and E138. TFPI K2 R107 is a central amino acid in the FXa inhibitory active site. The closest CA-CA distances between AB8D, Concizumab, and Marstacimab and TFPI K2 R107 are shown below. The closest CA-CA distance between the amino acid residues of antibody AB8D and amino acid residue R107 of TFPI K2 is 10.50 angstroms, between residue Y95 of the antibody AB8D light chain and residue R107 of TFPI K2. The closest CA-CA distance between the amino acid residues of antibody Concizumab and amino acid residue R107 of TFPI K2 is 8.69 angstroms, between residue Y59 of the antibody Concizumab heavy chain and residue R107 of TFPI K2. The closest CA-CA distance between the amino acid residues of antibody Marstacimab and amino acid residue R107 of TFPI K2 is 4.90 angstroms, between residue L104 of the antibody Marstacimab heavy chain and residue R107 of TFPI K2. By comparing the antigen epitope amino acids bound by three antibodies (AB8D, Marstacimab and Concizumab), it was found that the two antigen epitope amino acids T139 and T119 that the AB8D antibody binds to and / or blocks within 5 angstroms are not bound and / or blocked by the other two antibodies Concizumab and Marstacimab within 5 angstroms.On the other hand, the antibodies Concizumab and Marstacimab bind within 5 angstroms to R107 of the TFPI K2 domain. This amino acid is directly involved in inhibiting coagulation factor FXa and is located at the center of the active region. The antibody AB8D of the present invention does not directly bind to R107 within 5 angstroms, but rather binds to the amino acid Y109, located near R107 within 5 angstroms. The amino acid Y109 of the TFPI K2 domain also interacts significantly with coagulation factor FXa and is, after R107, a key amino acid for TFPI / FXa binding. Because the binding head or CDR surface area of the AB8D antibody is large, AB8D can block the binding of TFPI to coagulation factor FXa by binding to Y109 and shielding the nearby R107 region. The superposition of the AB8D / TFPI K2 and FXa / TFPI K2 complex structures showed that after superposition with the common TFPI K2, the AB8D antibody had spatial contact or steric hindrance with the coagulation factor FXa, indicating that AB8D competes with FXa for binding to TFPI K2. Due to the high affinity of the AB8D antibody, it blocks the binding between TFPI K2 and coagulation factor FXa.
[0212] Table 5. AB8D / TFPI K2 Antibody / Antigen Interaction Amino Acids (within 5 angstroms)
[0213] Example 10: Antibody / antigen kinetic simulation of anti-human TFPI antibodies
[0214] Gromacs version 2022.4 was used to perform 500 nanosecond molecular dynamics simulations of the AB8D antibody / TFPI K2 complex. The simulation system was constructed using the pdb2gmx tool within the Gromacs software package, employing the Charmm36 force field and the TIP3P water model. The initial antigen / antibody complex model was centered within a dodecahedral box, with the box's edges at least 10 angstroms from the model. The initial antigen / antibody complex model was dissolved in the TIP3P water model's water solvent by adding water molecules to the remaining space within the dodecahedral box. 0.15M NaCl ions were then added using the genion tool within Gromacs. After the addition of water molecules and 0.15M NaCl, the system was minimized using a steepest descent minimization procedure for up to 50,000 steps. Following energy minimization, the system was brought to a state suitable for dynamics simulations using two positionally constrained equilibrium simulations: isothermal isochoric NVT and isobaric isothermal NPT. Positionally constrained NVT and NPT equilibrium simulations were each performed for 2 ns. Finally, a 500 ns production dynamics simulation was performed at 300 K (V-rescale thermostat) and 1 atm (Parrinello-Rahman barostat). A Verlet cutoff scheme was used for non-covalent bond interactions. Long-range electrostatic interactions were calculated using the particle mesh PME summation scheme. All bond lengths were constrained using the LINCS algorithm. The dynamics simulation time step was 2 femtoseconds, and the low-precision coordinates of the simulation trajectory were saved every 0.5 ns. The complete 500 ns simulation trajectory file contains 1000 frames of the simulated system conformation.
[0215] Binding free energy calculations and amino acid residue decomposition of binding free energy were performed for a series of TFPI antigen / antibody complexes using gmx_MMPBSA versions 1.6.0-1.6.1. The Linux command for the gmx_MMPBSA binding free energy calculations is as follows: mpirun -np 40 gmx_MMPBSA -Oi mmpbsa.in -cs com.tpr -ci index.ndx -cg 1 13 -ct com_traj.xtc -cp topol.top -o FINAL_RESULTS_MMPBSA.dat -eo FINAL_RESULTS_MMPBSA.csv . In the above command, mpirun -np 40 executes 40 gmx_MMPBSA processes simultaneously. mmpbsa.in is the program run parameter file. com.tpr is the antigen / antibody complex topology parameter file. index.ndx is the group index file for the range of amino acid residues, NaCl ions, or water molecules in the simulation system. -cg 1 13 calculates the binding free energy between the amino acids in groups 1 and 13 in index.ndx. com_traj.xtc is the simulation trajectory file after removing the periodic boundary conditions. topol.top is the topology file for the dynamics simulation. FINAL_RESULTS_MMPBSA.dat and FINAL_RESULTS_MMPBSA.csv are the output result data files in different formats. The command line for the gmx_MMPBSA amino acid decomposition calculation is similar to the binding free energy calculation command line above. The specific Linux command is as follows: mpirun -np 40gmx_MMPBSA -Oi mmpbsa.in -cs com.tpr -ct com_traj.xtc -ci index.ndx -cg 1 13 -cp topol.top -o FINAL_RESULTS_MMPBSA.dat -eo FINAL_RESULTS_MMPBSA.csv -do FINAL_DECOMP_MMPBSA.dat -deo FINAL_DECOMP_MMPBSA.csv. FINAL_DECOMP_MMPBSA.dat and FINAL_DECOMP_MMPBSA.csv are the binding free energy data calculated for each amino acid decomposition in different formats.The solute polar solvation energy in the binding free energy calculation process is calculated according to the Poisson-Boltzmann (PB) equation, while the solute polar solvation energy in the binding free energy calculation process for each amino acid decomposition is calculated using the Generalized Bohn (GB) theory. Therefore, the total antigen / antibody binding free energy is slightly different from the sum of the binding free energies of each amino acid calculated for each amino acid decomposition.
[0216] The calculated antibody / antigen binding free energy results for AB8D / TFPI K2, Concizumab / TFPI K2, and Marstacimab / TFPI K2 are shown in Table 6. The contributions of key antigenic amino acids to the antigen / antibody binding free energy, calculated on an amino acid-by-amino acid basis, are shown in Table 7 (only amino acids with absolute free energy contributions greater than 0.5 kcal / mol are listed). In the AB8D / TFPI interaction, TFPI amino acid R124 significantly contributes to the antigen / antibody binding free energy. Amino acid R124 exhibits strong electrostatic attraction with E50 and H35 of the AB8D heavy chain (see Table 5), a cation-π interaction with the indole ring of W33 of the AB8D heavy chain, a hydrogen bond with S99 of the AB8D heavy chain, and a hydrogen bond with Y95 of the AB8D light chain. This indicates that the AB8D antibody binds to three amino acids within the TFPI K2 domain: Y113, L140, and Q121. These three amino acids have very weak interactions with Concizumab or Marstacimab, or in other words, they do not contribute significantly to the antigen / antibody binding free energy of Concizumab and Marstacimab. On the other hand, antibody AB8D has no significant interaction with amino acid R107 in the TFPI K2 domain, while Concizumab or Marstacimab have a strong interaction with R107 (Table 7).
[0217] Table 6. Antibody / antigen binding free energy
[0218] Table 7. Contribution of important TFPI antigen amino acids to antigen / antibody binding free energy calculated by each amino acid decomposition
[0219] Example 11: Molecular Structural Basis for the pH-dependent Change in Affinity of Anti-Human TFPI Antibodies for TFPI K2
[0220] Salt bridges or ion-pairing amino acids exhibit strong interactions. When ion-pairing amino acids are uncharged, strong hydrogen bonding interactions may still exist, but these interactions are much weaker than those between salt bridges or ion-pairing amino acids. The pH-dependent change in antibody / antigen affinity is primarily due to the presence of weakly ionized amino acids at the antibody / antigen binding interface, which participate in the binding process as salt bridges or ion pairs. When the pH changes near the pKa of these weakly ionized amino acids, the protonation state of these weakly ionized amino acids changes, thereby altering the affinity between the antibody and antigen. At pH <7, weakly ionized amino acids, primarily histidine, glutamic acid, and aspartic acid, undergo significant changes in protonation. The following structural predictions and descriptions of the changes in affinity of antibodies AB8D, Concizumab, and Marstacimab for the antigen TFPI K2 at pH <7 are provided. Tables 5, 8, and 9 list the interacting amino acids between AB8D, Concizumab, and Marstacimab and the antigen TFPI K2, respectively. As can be seen in Table 9, there are no significant salt bridge or ion-pair electrostatic interactions between the antibody Marstacimab and the antigen TFPI K2, so the affinity between Marstacimab and TFPI K2 should be minimally affected by pH changes at pH < 7. In Tables 5 and 8, AB8D and Concizumab each exhibit approximately five pairs of electrostatic interactions, and pH changes may affect the magnitude of these attractive forces.
[0221] Tables 10 and 11 present the pKa values of weakly ionized Glu / Asp amino acids at the binding interface of antibodies AB8D / TFPI K2 and Concizumab / TFPI K2, respectively (pKa values calculated using the program propka3). The E50 of the AB8D heavy chain, shown in Table 10, exhibits a pKa significantly higher than the normal pKa of 4.50 for glutamic acid. Heavy chain amino acid E50 participates in the interaction with TFPI K2 amino acid R124 (Figure 8) and contributes significantly to the affinity between AB8D and TFPI K2 (Tables 7, 12, and 13). Therefore, as the pH changes from 7 to 6, the protonation state of E50, which has a pKa of 6.75, decreases its ionization, significantly reducing the affinity between AB8D and TFPI K2 (Table 15). Another notable feature of the AB8D antibody / antigen structure is that the AB8D heavy chain histidine H35 is spatially adjacent to the heavy chain E50 amino acid, participating in the interaction with TFPI K2 R124 (Figure 8). The side chains of H35 and TFPI K2 R124 are 1 / 4 of the distance. At pH 7.4, the interaction between H35 and TFPI K2 R124 is van der Waals. When the pH decreases, for example, between pH 7.4 and 4.0, histidine H35 may become protonated, leading to electrostatic repulsion between TFPI K2 R124 and E50. In summary, due to the high pKa of 6.75 for heavy chain E50, a decrease in pH leads to a decrease in the electrostatic attraction between E50 and TFPI K2 R124. Furthermore, a decrease in pH may lead to protonation of the heavy chain H35 side chain and the resulting electrostatic repulsion between H35 and TFPI K2 R124. Therefore, these dual interactions of E50 and H35 may contribute to the pH-dependent antigen-binding affinity of the AB8D antibody. Furthermore, since the TFPI K2 R124 amino acid contributes significantly to the binding free energy between the AB8D antigen and antibody, the AB8D heavy chain E50 and / or H35 interacting with TFPI K2 R124 may be the primary amino acids responsible for the pH-dependent binding of the AB8D antibody within the pH range of 7.4-4.5. In Table 10, TFPI K2 E101 participates in the E101 / heavy chain R57 interaction (see Tables 7 and 13). These two amino acids contribute significantly to the binding free energy, resulting in a significant decrease in the affinity between AB8D and TFPI K2 when the pH changes from 5 to 4, past the E101 pKa of 4.50. Heavy chain E62 (pKa = 3.71) participates in the electrostatic attraction between E62 and K126. These two amino acids contribute little to the binding free energy, less than 0.5 kcal / mol or 0.51 kcal / mol, respectively (referring to Tables 7 and 13, the absolute value of E62's binding free energy contribution is less than 0.5 kcal / mol and is not shown in Table 13). In Table 10, TFPI K2 E123 (pKa = 3.36) participates in the electrostatic interaction between E123 and K52, contributing 0.96 kcal / mol or -0.57 kcal / mol, respectively, to the binding free energy, a modest contribution. Therefore, when the pH is lowered to below 3.71-3.36, the decrease in antibody / antigen affinity caused by antibody heavy chain E62 or TFPI K2E123 will not be significant.
[0222] Next, we analyze the antibody Concizumab. Table 11 shows that heavy chain D106 (pKa = 4.98) participates in the electrostatic interaction between heavy chain D106 and TFPI K2 R124. These two amino acids have a certain degree of interaction (see Tables 7, 8, and 14). Therefore, when the pH is lowered to approximately 4.98, the affinity between Concizumab and TFPI K2 decreases. TFPI K2 E101 (pKa = 4.96) participates in the electrostatic interaction with heavy chain R53. E101 contributes little to the binding free energy (0.66 kcal / mol), while R53 contributes significantly (-8.8 kcal / mol). Therefore, when the pH is lowered to approximately 4.98, the affinity of this ion pair E101 / R53 decreases significantly. E100 (pKa = 4.68) also participates in electrostatic interactions with antibody heavy chain R53, contributing significantly to the binding free energy (-2.33 kcal / mol, Table 7). Therefore, when the pH drops to around 4.68, the affinity of the antibody decreases significantly. In Table 11, light chain E31 (pKa = 3.98) participates in electrostatic interactions with TFPI K2 R124. Both amino acids contribute significantly to the binding free energy (Tables 7 and 14). When the pH drops to around 3.98, the binding affinity between Concizumab and TFPI K2 decreases significantly. Antibody heavy chain D62 (pKa = 3.93) participates in electrostatic interactions with TFPI K2 R107. Its contribution to the binding free energy is less than 0.5 kcal / mol and is not shown in Table 14. However, TFPI K2 R107 contributes significantly to the binding free energy (-3.5 kcal / mol, Table 7). Therefore, when the pH is lowered to approximately 3.93, the affinity of the antibody is still significantly reduced. Light chain D33 (pKa = 1.79) in Table 11 is relatively far from the guanidinium group of TFPI K2 R124 (5.18 angstroms) and contributes less to the binding free energy (0.56 kcal / mol, Table 14). Therefore, when the pH is lowered to approximately 1.79, the antibody / antigen affinity caused by light chain D33 does not change significantly before and after protonation.
[0223] According to the amino acid ionization formula, at pH = pKa, the ratio of protonated / unprotonated amino acid side chains is 1:1. At pH one unit below the pKa, the ratio is 10:1, meaning the amino acid side chains are considered uncharged. Therefore, in summary, the antibody AB8D's affinity for antigen is significantly reduced when the pH drops to one unit below the pKa, at pH 5.75 or 3.5, respectively. Concizumab's affinity for antigen is also significantly reduced at pH approximately 4.0 or 3.0, respectively.
[0224] In addition, if the antibody / antigen binding free energy can be further calculated for each weakly ionized amino acid in Tables 10 and 11 under the protonated or deprotonated state and the changes are compared (Table 15), and then discussed together with the contribution of charged amino acids to the binding free energy in Tables 7, 13 and 14, it may be possible to better describe and predict the characteristics of antibody / antigen affinity changes with pH.
[0225] Table 8. Concizumab / TFPI K2 Antibody / Antigen Interaction Amino Acids (within 5 angstroms)
[0226] Table 9. Marstacimab / TFPI K2 Antibody / Antigen Interaction Amino Acids (within 5 angstroms)
[0227] Table 10. pKa values of Glu / Asp amino acids involved in the interaction at the AB8D / TFPI K2 antibody / antigen binding interface
[0228] Table 11. pKa values of Glu / Asp amino acids involved in the interaction at the Concizumab / TFPI K2 antibody / antigen binding interface
[0229] Table 12. Pairwise energy decomposition of amino acids interacting with TFPI K2 amino acid R124 in the AB8D / TFPI K2 interaction.
[0230] Table 13. Contribution of AB8D antibody amino acids to the free energy of AB8D / TFPI K2 interaction
[0231] Table 14. Contribution of Concizumab Antibody Amino Acids to the Free Energy of Concizumab / TFPI K2 Interaction
[0232] Table 15. AB8D / TFPI K2 Antibody / Antigen Binding Free Energy
[0233] Example 12: Calculation of amino acid pKa values at the antigen / antibody binding interface of anti-human TFPI antibodies
[0234] Based on the above examples, the pKa values of amino acids Glu and Asp, particularly heavy chain E50, at the antigen / antibody binding interface were calculated for the other humanized antibodies obtained in Example 3. The results are shown in Tables 16 to 25. The results demonstrate that the humanized antibodies obtained in the present invention all have similar pH-dependent binding properties.
[0235] Table 16. pKa values of Glu / Asp amino acids involved in the interaction in the humanized antibody 1-1 / TFPI K2 antibody / antigen binding interface
[0236] Table 17. pKa values of Glu / Asp amino acids involved in the interaction in the humanized antibody 1-2 / TFPI K2 antibody / antigen binding interface
[0237] Table 18. pKa values of Glu / Asp amino acids involved in the interaction in the humanized antibody 1-4 / TFPI K2 antibody / antigen binding interface
[0238] Table 19. pKa values of Glu / Asp amino acids involved in the interaction in the humanized antibody 1-5 / TFPI K2 antibody / antigen binding interface
[0239] Table 20. pKa of Glu / Asp amino acids involved in the interaction in the humanized antibody 1-6 / TFPI K2 antibody / antigen binding interface
[0240] Table 21. pKa values of Glu / Asp amino acids involved in the interaction in the humanized antibody 1-7 / TFPI K2 antibody / antigen binding interface
[0241] Table 22. pKa values of Glu / Asp amino acids involved in the interaction in the humanized antibody 2-1 / TFPI K2 antibody / antigen binding interface
[0242] Table 23. pKa of Glu / Asp amino acids involved in the interaction in the humanized antibody 2-4 / TFPI K2 antibody / antigen binding interface
[0243] Table 24. pKa values of Glu / Asp amino acids involved in the interaction in the humanized antibody 2-6 / TFPI K2 antibody / antigen binding interface
[0244] Table 25. pKa values of Glu / Asp amino acids involved in the interaction in the humanized antibody 2-9 / TFPI K2 antibody / antigen binding interface
[0245] Example 13: Anti-human TFPI antibody affinity determination
[0246] The binding affinity constants of the anti-human TFPI antibody and human TFPI were measured according to the method of Example 2. The results of affinity measurement are shown in Table 26. The results show that the anti-human TFPI monoclonal antibody provided by the present invention has a very high binding affinity for human TFPI, K D Values can reach 10 -12 M order of magnitude.
[0247] Table 26. Affinity determination results of anti-human TFPI antibodies
[0248] Example 14. In vitro activity study of anti-human TFPI antibodies - TFPI neutralization assay: FVIIa / TF / FX inhibition
[0249] TFPI is an important negative regulator of the extrinsic coagulation pathway. TFPI's mechanism of action for coagulation inhibition is as follows: It is initiated through direct binding of the K2 domain to FXa, inhibiting FXa activity and forming a TFPI / FXa complex; within the TFPI / FXa complex, the K1 domain of TFPI binds to FVIIa in the tissue factor complex FVIIa / TF to form a quaternary complex, inhibiting the activity of the FVIIa / TF complex and preventing further activation of FX to FXa. The TFPI monoclonal antibody of the present invention is designed to bind to the K2 domain of TFPI, blocking the binding of TFPI to FXa and complex formation, thereby restoring the effect of the tissue factor complex FVIIa / TF on FX activation and promoting FXa production. In this assay, FVIIa, TF, TFPI, and FX were incubated with the test substance, and the absorbance of the reaction catalyzed by FXa with the substrate S-2765 was used to evaluate the effectiveness of the test substance in neutralizing TFPI activity.
[0250] The results of the study showed that the 22 humanized antibodies of the present invention all have the biological effect of restoring the TFPI-mediated inhibition of the FVIIa / TF / FX coagulation pathway and have a neutralizing effect on the activity of TFPI. 50 They were 8.64-22.12 μg / mL respectively.
[0251] Example 15: In vivo pharmacodynamic evaluation of anti-human TFPI antibodies
[0252] Forty male New Zealand White rabbits were randomly divided into five groups based on body weight. The test substance or vehicle was injected subcutaneously into the nape of the neck of each rabbit on Day 1. All rabbits received an anti-FVIII antibody injection into the ear vein on Day 8 to induce hemophilia A (HA). Forty-five minutes after administration of the anti-FVIII antibody on Day 8, nails were cut to induce cuticle bleeding, and initial bleeding time and volume were measured. Blood samples were collected on Day 8 before HA model initiation (before anti-FVIII antibody injection), before bleeding model initiation (45 minutes after anti-FVIII antibody injection), and 60 minutes after bleeding model initiation. Plasma activated partial thromboplastin time (APTT), diluted prothrombin time (dPT), and factor VIII (FVIII) activity were measured.
[0253] The results showed that a single subcutaneous injection of 10 mg / kg of the positive control, Marstacimab (generic with reference to PF-06741086), significantly reduced bleeding volume and shortened initial bleeding time to some extent after 7 days of administration. A single subcutaneous injection of 5 mg / kg, 10 mg / kg, and 20 mg / kg of AB8D resulted in a dose-dependent reduction in bleeding volume and shortened initial bleeding time after 7 days of administration (with statistically significant differences observed at the 20 mg / kg dose). A single subcutaneous injection of 10 mg / kg and 20 mg / kg of AB8D significantly shortened the dPT (dPT) before and 105 minutes after modeling) in HA model rabbits 7 days after administration. The results indicate that under these experimental conditions, AB8D can shorten initial bleeding time and dPT, reduce bleeding volume, and demonstrate a therapeutic effect.
[0254] Table 27. Bleeding volume and initial hemostasis time (n=8) Note: Compared with the G1 group at the same time point, *P<0.05; **P<0.01; ***P<0.001, and the rest are the same.
[0255] Table 28. Diluted prothrombin time (n=7-8)
[0256] Example 16 Safety Evaluation of Anti-Human TFPI Antibodies in Rhesus Monkeys
[0257] In a four-week repeated-dose toxicity study with a recovery period of four weeks and a safety pharmacology study of the central nervous system, cardiovascular system, and respiratory system of rhesus monkeys after subcutaneous injection of AB8D monoclonal antibody injection, AB8D monoclonal antibody injection had no significant effect on the central nervous system, cardiovascular system, and respiratory system of rhesus monkeys, and was non-irritating to the local area of administration.
[0258] In a dose-ranging and maximum tolerated dose study in rhesus monkeys administered subcutaneously with a stock solution of the AB8D monoclonal antibody, all animals survived until planned autopsy. Female animals in the test article group experienced intermittent watery / loose stools and weight loss. At the end of the observation period, prolonged APTT, elevated serum BUN and CREA, and decreased Na and Cl levels were observed. Histopathological examination revealed mild cardiac myocyte degeneration and mild macrophage accumulation in the lungs. Due to the limited number of animals, the relationship between these abnormalities and the test article could not be determined.
[0259] In a four-week repeated-dose toxicity study in rhesus monkeys following subcutaneous administration of AB8D monoclonal antibody injection with a four-week recovery period, visible changes in the repeated-dose toxicity study in rhesus monkeys included: compared with the vehicle control group, when the test article dose was ≥10 mg / kg, plasma fibrinogen levels in both male and female animals decreased from 168 hours after the first dose to the end of the recovery period (D57); when the test article was ≥10 mg / kg, D-dimer levels in both male and female animals increased or showed an increasing trend from 24 hours after the first dose to D29 at the end of the dosing period, and when the dose was ≥30 mg / kg, an increasing trend of D-dimer levels in both male and female animals was observed at D57 at the end of the recovery period; histopathological examination found that no thrombosis was observed during or after the test at doses of 10 and 30 mg / kg, and no test article-related toxicity changes were observed.
[0260] In the in vitro hemolysis test of AB8D monoclonal antibody injection, AB8D monoclonal antibody injection did not cause hemolysis and agglutination reactions of rabbit red blood cells in vitro and can be used for subcutaneous injection.
[0261] In the immunotoxicity evaluation of the AB8D monoclonal antibody injection administered subcutaneously to rhesus monkeys for four weeks and repeated administration for four weeks, no abnormal changes in the immunotoxicity evaluation indicators related to the test article were observed. Specifically, the changes included hematological leukocyte indicators, serum biochemical albumin and globulin levels, lymphocyte immune characteristics (CD3 + CD4 + 、CD3 + CD8 + 、CD3 + CD4 + / CD3 + CD8 + 、CD20 +, CD16+), immunoglobulins and complement (IgA, IgG, IgM, C3, C4), immune organ weights (spleen and thymus), gross anatomical observation and histopathological examination of spleen / thymus / lymph nodes (draining inguinal lymph nodes and mesenteric lymph nodes) / bone marrow.
[0262] In the study of cytokine release after incubation of AB8D monoclonal antibody injection with human peripheral blood mononuclear cells (PBMC), AB8D monoclonal antibody injection did not stimulate PBMC cells to release IL-2, IL-4, IL-6, IL-10, TNF-α and INF-γ.
[0263] Example 17: Pharmacokinetic Study of Anti-Human TFPI Antibodies in Rhesus Monkeys
[0264] Rhesus monkeys were randomly divided into two groups (6 monkeys / group, half male and half female). Each group received a single subcutaneous injection of 15 mg / kg or 50 mg / kg of the AB8D humanized antibody. The pharmacokinetic parameters obtained are shown in Table 29. At a subcutaneous injection of 50 mg / kg, the half-life of the AB8D humanized antibody reached 136 hours.
[0265] Table 29. Pharmacokinetic parameters in rhesus monkeys
[0266] Example 18 Safety evaluation of anti-human TFPI antibodies in healthy adult subjects in China
[0267] When healthy subjects received a single dose of 30-200 mg of AB8D monoclonal antibody, the incidence of adverse events showed a certain dose-relatedness. The vast majority of adverse events were grade 1 in severity (according to CTCAE 5.0 grading), and only one grade II adverse event occurred, which was determined by the investigator to be unrelated to the trial drug. All adverse events were transient and the outcomes were all recovery. No serious adverse events, adverse events leading to withdrawal, or deaths were reported. No significant and meaningful trend in the important safety indicators of all subjects was observed. No other potentially important safety issues related to AB8D monoclonal antibody were reported. Healthy subjects can tolerate a single subcutaneous injection of 10-200 mg of AB8D monoclonal antibody, with overall safety and tolerability.
[0268] Internationally, multiple drugs with the same target (anti-TFPI monoclonal antibodies) are being developed for the treatment of hemophilia A and B. Only some data for Concizumab and Marstacimab have been disclosed. Concizumab has been launched in Canada, Japan, Switzerland and other regions, and the highest global research and development stage of Marstacimab is Phase III clinical trials. Adverse events reported for Concizumab in healthy subjects were mild or moderate in severity, and the most common adverse reactions were headache, common cold, fatigue or flu. Adverse events reported for Marstacimab in healthy subjects were mild or moderate in severity, and the most common adverse events included headache, fatigue and local or systemic pain / discomfort. In the Phase I clinical trial of AB8D monoclonal antibody, the severity of the adverse events reported were all mild, and no headache, fatigue or systemic pain / discomfort were reported. Its safety is better than that of similar products.
[0269] Example 19: Clinical Pharmacokinetic Study of Single-Dose Antibody to Healthy Chinese Adults
[0270] Active AB8D concentrations in human plasma were quantitatively determined using an ELISA assay. Human TFPI / His (purchased from ACROBiosystem, catalog number TFI-H5226) was diluted to 0.1 μg / ml in 1× PBS buffer and added to a 96-well ELISA plate at a volume of 100 μl / well. The plate was incubated at 4°C for 16–20 hours. The PBS buffer was discarded from the 96-well plate, and 200 μl / well of PBST / 1.5% BSA was added and blocked at room temperature for 1 hour. The plate was washed three times with PBST (pH 7.4, PBS containing 0.05% Tween 20). The plasma to be tested was then added at 100 μl / well and incubated at room temperature for 1 hour. After washing the plate three times with PBST, 10 μg / ml of biotin-labeled mouse anti-AB8D idiotypic antibody (AP651651, Anyuan Pharmaceutical) was added at 100 μl / well and incubated at room temperature for 1 hour. After washing the plate three times with PBST, add 100 μl / well of a 1:5000 dilution of SA-Avidin-HRP and incubate at room temperature for 1 hour. After washing the plate three times with PBST, add 100 μl / well of TMB and incubate at room temperature for 5-10 minutes. Terminate the reaction by adding 50 μl / well of 0.2 M sulfuric acid. Read the absorbance at dual wavelengths of 450 / 620 nm using a microplate reader.
[0271] In terms of pharmacokinetics, the AB8D humanized antibody exhibited nonlinear pharmacokinetic characteristics within the experimental dose range and exhibited a target-mediated drug disposition (TMDD) effect. The pharmacokinetic parameters for healthy subjects are shown in Table 30. The time to peak (Tmax) after subcutaneous administration in healthy subjects ranged from 31h to 36h; the average t 1 / 2The half-life ranges from 104 to 145 hours, and increases with increasing dose. Compared with drugs with the same target, the peak time is faster and the half-life is longer, which are both PK characteristics of TMDD.
[0272] Table 30. Pharmacokinetic parameters in healthy subjects
[0273] Example 20: Clinical pharmacodynamics study of single-dose anti-human TFPI antibody in healthy Chinese adults
[0274] A double-antibody sandwich ELISA was used to quantitatively detect the concentration of TFPI in human plasma. AB8D was diluted to 5 μg / ml in 1× PBS buffer and added to a 96-well ELISA plate at a volume of 100 μl / well. The plate was incubated at 4°C for 16-20 hours. The PBS buffer in the 96-well plate was discarded and 200 μl / well of PBST / 1.5% BSA was added and blocked at room temperature for 1 hour. The plate was washed three times with PBST (pH 7.4, PBS containing 0.05% Tween 20) buffer and the plasma to be tested was added at 100 μl / well and incubated at room temperature for 1.0 hour. After washing the plate three times with PBST, 0.1 μg / ml rabbit anti-human TFPI antibody (purchased from Abcam ab274436) was added at 100 μl / well and incubated at room temperature for 1 hour. After washing the plate three times with PBST, add 100 μl / well of a 1:80,000 dilution of Peroxidase-conjugated AffiniPure Donkey Anti-Rabbit IgG (H+L) (purchased from Jackson ImmunoResearch) and incubate at room temperature for 1 hour. After washing the plate three times with PBST, add 100 μl / well of TMB and incubate at room temperature for 5-10 minutes. Terminate the reaction by adding 50 μl / well of 0.2 M sulfuric acid. Read absorbance at dual wavelengths of 450 / 620 nm using a microplate reader.
[0275] A dose-dependent reduction in free TFPI levels was observed across 30mg-200mg of the AB8D monoclonal antibody. TFPI rapidly decreased within 8 hours after the first dose of AB8D monoclonal antibody, returning to baseline levels around day 14 in the low-dose group (30mg) and around day 21 in the high-dose group (200mg).
[0276] While the preferred embodiment of the present invention has been illustrated and described, it will be appreciated that various modifications may be made by those skilled in the art in light of the teachings herein without departing from the scope of the invention.
[0277] All documents mentioned herein are incorporated by reference in this application to the same extent as if each document were individually incorporated by reference. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various modifications and alterations to the present invention, and that such equivalents are also within the scope of the claims appended hereto.
Claims
1. An antibody or antigen-binding fragment thereof that binds to tissue factor pathway inhibitor (TFPI), wherein: The antibody or antigen-binding fragment thereof does not interact and / or block R107 in the tissue factor pathway inhibitor within 5 angstroms.
2. The antibody or antigen-binding fragment thereof according to claim 1, wherein The antibody or antigen-binding fragment thereof interacts with and / or blocks at least one of the following amino acid positions in the tissue factor pathway inhibitor at 5 angstroms or closer: Y109, I110, T111, R124, K126 and E138.
3. The antibody or antigen-binding fragment thereof according to claim 2, wherein: The antibody or antigen-binding fragment thereof also interacts and / or blocks at least one of the following amino acid positions in the tissue factor pathway inhibitor at 5 angstroms or less: T139, T119, E101, Y113, F114, N116, Q118, Q121, C122, E123, F125 and L140.
4. The antibody or antigen-binding fragment thereof according to claim 2, wherein The antibody or antigen-binding fragment thereof also interacts and / or blocks at least one of the following amino acid positions in the tissue factor pathway inhibitor at 5 angstroms or closer: R112, K93, K120, K126 and K144, preferably R124 and K126.
5. The antibody or antigen-binding fragment thereof according to claim 1, wherein: The amino acid sequence of the tissue factor pathway inhibitor is shown in SEQ ID NO:
1.
6. The antibody or antigen-binding fragment thereof according to claim 1, wherein: The antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: (a) the heavy chain variable region defined according to the Kabat numbering system comprises at least one, two or three complementarity determining regions (CDRs) selected from the group consisting of: (1) HCDR1, which has an amino acid sequence of SYWMH; (2) HCDR2 having an amino acid sequence of EIKPD X1GRI X2YNEKFKT, wherein X1 is selected from Q, H or K, and X2 is selected from N, D or H; and (3) HCDR3 having an amino acid sequence of SS X3 X4D X5A X6DY, wherein X3 is selected from V or H, X4 is selected from V, I, F, Y or L, X5 is selected from V, D, T or E, and X6 is selected from M, L, I, E, V or D; And / or, the light chain variable region it comprises comprises at least one, two or three complementarity determining regions (CDRs) selected from the group consisting of: (4) LCDR1, which has an amino acid sequence of SASSVSSSYLY; (5) LCDR2 having the amino acid sequence of GTSILAS; and (6) LCDR3 having an amino acid sequence of HQWX7X8YPFT, wherein X7 is selected from S or T, and X8 is selected from H, Y or F; or, (b) a heavy chain variable region as defined according to the IMGT numbering system comprising at least one, two or three complementarity determining regions (CDRs) selected from the group consisting of: (1) HCDR1, which has an amino acid sequence of GYTFTSYW; (2) HCDR2 having the amino acid sequence of IKPD X1GRI, wherein X1 is selected from Q, H or K; and (3) HCDR3 having an amino acid sequence of ARSS X3 X4D X5A X6DY, wherein X3 is selected from V or H, X4 is selected from V, I, F, Y or L, X5 is selected from V, D, T or E, and X6 is selected from M, L, I, E, V or D; And / or, the light chain variable region it comprises comprises at least one, two or three complementarity determining regions (CDRs) selected from the group consisting of: (4) LCDR1, which has an amino acid sequence of SSVSSSY; (5) LCDR2 having the amino acid sequence of GTS; and (6) LCDR3 having an amino acid sequence of HQWX7X8YPFT, wherein X7 is selected from S or T, and X8 is selected from H, Y or F.
7. The antibody or antigen-binding fragment thereof according to claim 6, characterized in that: The antibody or antigen-binding fragment thereof comprises 3 VH variable region CDRs and 3 VL variable region CDRs selected from the group consisting of: (1) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequence shown in SEQ ID NO: 46, 47, 48, 49, 50 or 51, respectively, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (2) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequence shown in SEQ ID NO: 46, 47, 56, 49, 50 or 51, respectively, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (3) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequence shown in SEQ ID NO: 46, 47, 58, 49, 50 or 51, respectively, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (4) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 60, 48, 49, 50 or 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (5) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequence shown in SEQ ID NO: 46, 61, 48, 49, 50 or 51, respectively, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences (6) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequence shown in SEQ ID NO: 46, 63, 48, 49, 50 or 51, respectively, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (7) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequence shown in SEQ ID NO: 46, 65, 48, 49, 50 or 51, respectively, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (8) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequence shown in SEQ ID NO: 46, 47, 48, 49, 50 or 66, respectively, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (9) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequence shown in SEQ ID NO: 46, 47, 48, 49, 50 or 67, respectively, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (10) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 48, 49, 50 or 68, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (11) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 63, 58, 49, 50 or 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (12) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 69, 49, 50 or 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (13) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 71, 49, 50 or 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (14) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequence shown in SEQ ID NO: 46, 47, 73, 49, 50 or 51, respectively, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (15) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 75, 49, 50 or 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (16) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 77, 49, 50 or 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (17) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 79, 49, 50 or 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (18) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 81, 49, 50 or 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (19) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 83, 49, 50 or 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (20) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 85, 49, 50 or 51, respectively, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (21) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequence shown in SEQ ID NO: 46, 47, 87, 49, 50 or 51, respectively, or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (22) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 46, 47, 89, 49, 50 or 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (23) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 54, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (24) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 57, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (25) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 59, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (26) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 62, 54, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (27) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 65, 54, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (28) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 54, 55, Gly-Thr-Ser or SEQ ID NO: 66, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (29) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 54, 55, Gly-Thr-Ser or SEQ ID NO: 67, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (30) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 54, 55, Gly-Thr-Ser or SEQ ID NO: 68, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (31) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 64, 59, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (32) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 70, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (33) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 72, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (34) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 74, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (35) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 76, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (36) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 78, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (37) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 80, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (38) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 82, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (39) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 84, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (40) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 86, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (41) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 88, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences; (42) Its HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 have the sequences shown in SEQ ID NO: 52, 53, 90, 55, Gly-Thr-Ser or SEQ ID NO: 51, respectively, or have one or more amino acid substitutions, deletions or additions (e.g., 1, 2 or 3 substitutions, deletions or additions) compared with any of the above sequences.
8. The antibody or antigen-binding fragment thereof according to claim 6, wherein: The antibody or antigen-binding fragment thereof is humanized.
9. The antibody or antigen-binding fragment thereof according to claim 8, characterized in that: The antibody or antigen-binding fragment thereof is selected from the following VH and VL sequence combinations: 1) the VH domain comprises the amino acid sequence as shown in SEQ ID NO: 2, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as shown in SEQ ID NO: 3, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); 2) the VH domain comprises the amino acid sequence as shown in SEQ ID NO:4, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as shown in SEQ ID NO:5, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); 3) the VH domain comprises the amino acid sequence as shown in SEQ ID NO: 6, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as shown in SEQ ID NO: 7, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); 4) the VH domain comprises the amino acid sequence as shown in SEQ ID NO: 8, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as shown in SEQ ID NO: 9, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); 5) the VH domain comprises the amino acid sequence as shown in SEQ ID NO: 10, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as shown in SEQ ID NO: 11, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); 6) the VH domain comprises the amino acid sequence as shown in SEQ ID NO: 12, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as shown in SEQ ID NO: 13, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); 7) the VH domain comprises the amino acid sequence as shown in SEQ ID NO: 14, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as shown in SEQ ID NO: 15, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)). such as sequences that are at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical or have one or more amino acid substitutions (e.g., conservative substitutions); 8) the VH domain comprises the amino acid sequence as shown in SEQ ID NO: 16, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as shown in SEQ ID NO: 17, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); 9) the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 18, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 19, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); 10) a VH domain comprising an amino acid sequence as set forth in SEQ ID NO: 20, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and a VL domain comprising an amino acid sequence as set forth in SEQ ID NO: 21, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); 11) the VH domain comprises the amino acid sequence as shown in SEQ ID NO: 22, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as shown in SEQ ID NO: 23, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); 12) the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 24, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 25, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); 13) the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 26, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 27, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); 14) The VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 28, or is substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical) or has one or more amino acid substitutions (e.g., conservative substitutions). and a VL domain comprising an amino acid sequence as shown in SEQ ID NO: 29, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); 15) the VH domain comprises the amino acid sequence as shown in SEQ ID NO: 30, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as shown in SEQ ID NO: 31, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); 16) the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 32, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 33, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); 17) the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 34, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 35, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); 18) the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 36, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 37, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); 19) a VH domain comprising the amino acid sequence as set forth in SEQ ID NO: 38, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and a VL domain comprising the amino acid sequence as set forth in SEQ ID NO: 39, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); 20) the VH domain comprises the amino acid sequence as shown in SEQ ID NO: 40, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as shown in SEQ ID NO: 41, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); 21) the VH domain comprises the amino acid sequence as set forth in SEQ ID NO: 42, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as set forth in SEQ ID NO: 43, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity, or having one or more amino acid substitutions (e.g., conservative substitutions)); 22) The VH domain comprises the amino acid sequence as shown in SEQ ID NO:44, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)); and its VL domain comprises the amino acid sequence as shown in SEQ ID NO:45, or a sequence substantially identical to the above sequence (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identity or having one or more amino acid substitutions (e.g., conservative substitutions)).
10. The antibody or antigen-binding fragment thereof according to claim 1, wherein: It is a full length antibody, Fab, Fab', (Fab')2, Fd, Fv, dAb, scFv or scFv-scFv.
11. The antibody or antigen-binding fragment thereof according to claim 1, wherein: The antibody comprises a heavy chain constant region and a light chain constant region derived from human immunoglobulin; preferably, the heavy chain constant region is selected from the heavy chain constant regions of human IgG1, IgG2, IgG3 and IgG4; and, the heavy chain constant region has a native sequence or a sequence having one or more amino acid substitutions, deletions or additions compared to the native sequence from which it is derived; and the light chain constant region is preferably the constant region of a human κ light chain.
12. The antibody or antigen-binding fragment thereof according to claim 11, wherein: The antibody comprises a heavy chain constant region of human IgG4, and the heavy chain constant region contains an amino acid mutation of S228P.
13. A bispecific antibody, or antigen binding portion thereof, comprising the antibody, or antigen binding portion thereof, of any one of claims 1 to 12 linked to a second antibody, or antigen binding portion thereof.
14. The bispecific antibody or antigen-binding portion thereof according to claim 13, wherein: The second antibody, or antigen binding portion thereof, binds tissue factor pathway inhibitor.
15. A DNA molecule encoding the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14.
16. A vector comprising the DNA molecule according to claim 15.
17. A host cell comprising the vector according to claim 16, preferably the host cell comprises a prokaryotic cell, a yeast or a mammalian cell, more preferably a CHO cell.
18. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, and a pharmaceutically acceptable excipient, carrier or diluent.
19. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14 or the pharmaceutical composition according to claim 18 in the preparation of a medicament for preventing or treating a disease or condition caused by inherited or acquired coagulation factor deficiency.
20. A method for preventing or treating a disease or condition caused by inherited or acquired coagulation factor deficiency, comprising administering an effective dose of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14 or the pharmaceutical composition according to claim 18 to a patient in need thereof.
21. The use according to claim 19 or the method according to claim 20, characterized in that The disease is hemophilia.
22. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14 or the pharmaceutical composition according to claim 18 in the preparation of a medicament for preventing or treating a hereditary coagulation disease.
23. A method for preventing or treating an inherited coagulation disease, comprising administering an effective dose of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14 or the pharmaceutical composition according to claim 18 to a patient in need thereof.
24. The use according to claim 22 or the method according to claim 23, characterized in that The disease is thrombasthenia or giant platelet syndrome.
Citation Information
Patent Citations
Method for recovering mutant cells
US4818679A
Single polypeptide chain binding molecules
US4946778A
Single polypeptide chain binding molecules
US5260203A
Single polypeptide chain binding molecules
WO1988001649A1
Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
CN106687482A
